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Depressive disorders (DD) are a leading cause of disability worldwide and display 
diverse symptoms including anhedonia, melancholia, decreased concentration, sleep 
and appetite disturbances, and suicidal thoughts and acts. Current available medications 
are still ineffective for more than 30% of patients, suggesting DD are multi-faceted 
heterogeneous disorders. Despite intense research, as yet there are no widely used 
biological diagnostic tests for DD. Since DD are likely a manifestation of both genetic and 
environmental factors, gene expression of peripheral blood leukocyte allows for a non-
invasive means to evaluate trait- and state-dependent neurophysiological dysregulation. 
In this dissertation, we employed real-time quantitative polymerase chain reaction 
(qPCR) to evaluate differences between healthy controls and patients with medication-
refractory depression, for a panel of candidate genes previously implicated in 
depression as well as novel genes implicated in related neurological disorders. Chapter 1 
begins with an overview of the multiple domains involved in depression and of previous 
literature findings evaluating protein and gene expression. Chapter 2 describes one of 
our studies of gene expression of a small panel of 14 genes involved in the immune and 
stress response in 19 patients with medication-refractory depression, before and 
following symptom improvement, compared to 20 healthy controls. We found that 





and IL-6, transcription factor NFkB1, the serotonin receptor HTR1D, GABAA modulator 
DBI, and the adrenergic receptors ADR2A and ADRB1. Furthermore, the dopamine 
receptor DRD4, the glucocorticoid receptor NR3C1, and SULT1A1 displayed acute 
changes following treatment, though no differences were observed Pretreatment. In 
Chapter 3, we describe another gene expression study with results using a larger sample 
size (42 patients and 38 controls) and an expanded gene panel (46 genes) that includes 
candidate genes from diverse biological pathways. In this study, we found upregulation 
of IL-10 and IL-6 as well as dysregulation in the amyloid precursor protein, neuregulin-1, 
and several ion channels that have roles in anxiety, pain, and fatigue. Finally, Chapter 4 
summarizes results from both studies and discusses future research into promising 
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Depressive disorders (DD) are a rapidly growing burden on society, with up to 
20% lifetime prevalence and estimated to become the second leading cause of disability 
by 2020 (World Health Organization, 2004). Symptoms include low self-esteem, feelings 
of guilt, anhedonia, decreased motivation and concentration, disruption in eating and 
sleeping patterns, and importantly, suicidal thoughts and acts. Though diagnosis only 
requires having some of these symptoms for a period of 2 weeks, DD are often chronic 
and present with recurring lifetime episodes (Maletic et al., 2007). In other words, this 
disease pattern suggests chronic imbalances with state-dependent changes due to acute 
triggers.  
For over 50 years, the dominate hypothesis has been that DD result from low 
synaptic availability of the monoamines serotonin, dopamine, and norepinephrine 
(Schildkraut, 1965). This "monoamine hypothesis" still guides the development of the 
majority of currently available antidepressants. However, in a great proportion of cases 
treatments are ineffective or only partially effective. The STAR*D trial showed only 30% 
remission rate after the first line of antidepressant using a selective serotonin reuptake 
inhibitor and marked decreased  effectiveness of subsequent similar medications. These 
data strongly indicate the heterogeneity of disease mechanisms and the inadequacy of 
the monoamine hypothesis as a model of treatment (Trivedi et al., 2006). Other 
research to date has implicated diverse contributions to the mechanism of DD beyond 
low monoamine synaptic availability. These include dysfunction/imbalances in: the 




DNA regulation, and environmental effects (Krishnan and Nestler, 2008, 2010). 
Depression is thus a multifaceted and dynamic disease and its symptomatic episodes are 
likely the result of internal and external influences (Maletic, 2007). 
Current diagnosis of DD relies solely on clinical assessment. There are many 
forms of DD and many likely etiologies. Nevertheless, most are treated the same. Drug 
development as well as patient therapy would benefit from a better understanding of 
disease mechanisms and if we could evaluate a patient’s disease as well as medication 
response via reliable biological tests (biomarkers). One promising approach that might 
allow for this better understanding as well as individualized therapy is to examine 
differences in mRNA gene expression, which can demonstrate the effects of genetic, 
epigenetic, and environmental influences. mRNA results from transcription of DNA, the 
genetic code that remains largely invariable throughout life. mRNA translation, in turn, 
results in the synthesis of proteins which mediate nearly all biological processes. The 
formation of mRNA depends not only upon our DNA genetic code (which is why DNA 
approaches to predict or understand DD have been so inadequate), but also upon many 
factors that affect which sections of DNA are transcribed into mRNA. This is a complex 
process with multiple regulation steps allowing control of specific transcripts, for 
example: 1) control of unraveling DNA from histones 2) DNA methylation and 
hydroxylation that impedes DNA binding of necessary machinery for gene expression, 
and 3) diverse families of transcription factors that bind to upstream sites allowing for 
coordinated responses. In short, which mRNA is generated is a result not only of our 




are affected by the physiological environment of the person. So, when we look at mRNA 
expression, we look at our inborn biology and the effects of our environment on its 
expression. We hypothesize, then, that mRNA gene expression may be used to better 
understand physiological states in depressed individuals. Altered expression of some 
specific genes may be associated with chronic imbalances, while others may change 
with symptomology. 
 Interestingly, and important to the practicality of measuring such mRNA gene 
expression, many of the pathways implicated in DD have not only central (brain) 
components, but also peripheral (outside the CNS) ones. For example, blood leukocytes 
mediate the immune and inflammatory response to stress, and display many of the 
same receptors that are also found in central brain cells (Gladkevich et al., 2004; Sullivan 
et al., 2006). Additionally, other factors implicated in DD can be measured in peripheral 
blood cells. This may initially seem surprising, but one must understand that white blood 
cells (WBCs) are exposed to the influences of both central and peripheral processes and 
factors. Thus, the use of blood test to evaluate DD would provide an easy and relatively 
inexpensive means to diagnose disease as well as individually tailor and follow 
treatment effects. To this aim, in this dissertation, we have examined WBC gene 
expression in patients with severe medication-refractory depression, as well as changes 







Peripheral gene expression using qPCR to explore molecular  
biology of depression 
While DNA remains largely unchanged across cell types and an organism’s life, 
mRNA expression is labile, being greatly affected by environmental factors and as such, 
can describe current physiological states. Although postmortem brain tissue has 
provided interesting observations of the anatomical differences between suicide and 
nonsuicide deaths, potential confounders such as temperature, tissue pH, agonal 
factors, and variation in cause of death make these data difficult to interpret (Mehta et 
al., 2010). Interestingly, Sullivan et al. found that whole blood displays high gene 
expression correlation with multiple regions of the central nervous system and could 
therefore be informative as to the state of the brain (Liew et al., 2006; Sullivan et al., 
2006). This is not surprising, given that white blood cells or leukocytes (composed of cell 
types including lymphocytes, monocytes, and macrophages) are exposed to the same 
chemical milieu as are neurons, including hormones, neurotransmitters, and growth 
factors (Gladkevich et al., 2004). The development of microarrays has allowed 
investigation of tens of thousands of genes at a time, providing a global overview of 
gene expression (Forster et al., 2003). Essentially, known sequences are immobilized on 
a matrix chip in distinct sections and a sample of mixed transcripts is overlaid. When the 
immobilized transcripts bind to those in the sample, they emit a measurable fluorescent 
signal. This allows investigation of novel disease contributors before and after 
treatments. However, due to their large scope and lack of distinct a priori hypotheses, 




reproducibility across research groups, thus making them a semiquantitative technique 
(Forster et al., 2003; Walker and Hughes, 2008; Mehta et al., 2010).  
Unlike microarrays, real-time quantitative polymerase chain reaction (qPCR) 
allows measurements of gene transcripts in between rounds of DNA replication. These 
are later normalized to one or several constitutively expressed internal controls and 
quantified during stable periods of replication. Most noteworthy, the qPCR technique 
displays greater sensitivity than microarrays, and given that it has a considerably 
narrower scope with genes of interest chosen a priori, it has historically been used to 
validate candidate genes from microarrays, though this technique is not without its own 
technical challenges (Bustin and Mueller, 2005). Given that WBCs express 
neurotransmitter receptors and are an integral part of the immune/stress response, 
biological systems that are found to be dysregulated in depressive disorders, qPCR gene 
expression from blood using hypothesis-driven target genes could result in diagnostic 
biomarkers for DD. If mRNA gene expression could represent a temporal snapshot of a 
person’s current physiological state, subjects in different symptomatic states including 
depressive, manic, euthymic, or remissive periods, may also be distinguished 
physiologically by gene expression (Bustin and Mueller, 2005; Iga et al., 2008). 
Therefore, studies that examine blood before and after symptom remission are valuable 
in understanding potential novel mechanisms of depression as well as in identifying 
biomarkers to monitor treatment response. Below we will describe some of the 





Roles of serotonin, norepinephrine, and dopamine in depression 
The monoamines were implicated in depressive disorders based on some 
serendipitous observations that drugs modulating levels of monoamines such as the 
catecholamines norepinephrine and dopamine or the indolamine serotonin could result 
in depressive symptoms or their alleviation (Schildkraut, 1965). For example, the 
monoamine oxidase inhibitor (MAOI) iproniazid, which hinders monoamine metabolism, 
was found to improve mood in patients treated for tuberculosis, while the 
antihypertensive drug reserpine, which lowers norepinephrine and serotonin synaptic 
levels by preventing their packaging in to vesicles, worsened depressive symptoms 
(Schildkraut, 1965; Lopez-Munoz and Alamo, 2009). These early pharmacological 
observations shifted the viewing of depression as a purely psychological disease to one 
with a biological basis.  
 
Serotonin 
In addition to reserpine’s depressive effects, further evidence of a role for 
serotonin in depression came from observed decreased levels of serotonin in the brain 
and its metabolite in the cerebral spinal fluid (CSF) of patients with depression 
(Schildkraut et al., 1965). Furthermore, depletion of tryptophan (a necessary precursor 
for serotonin synthesis) in patients in remission after administration of selective 
serotonin reuptake inhibitors (SSRIs), results in rapid emergence of depressive 
symptoms (Krishnan and Nestler, 2008; Nemeroff and Owens, 2009). More recent work 




expression occur with medication treatment. For example, Belzeaux et al. observed no 
differences in the serotonin receptors 1B and 2A at baseline, yet a significant increase in 
both following antidepressant treatment (Belzeaux et al., 2010). Iga et al. found that 
mRNA levels for the serotonin transporter (5HTT) in leukocytes were elevated at 
baseline in antidepressant-naïve depressed subjects compared to controls, and then 
decreased significantly at 8 weeks following treatment with the SSRI paroxetine (Iga et 
al., 2005). These changes are relevant given that SSRIs and NRIs require several weeks 
for a clinical effect. It is important to note that mRNA levels and their proteins can have 
complicated interactions, such that increased mRNA gene expression need not correlate 
with the increased number of receptor binding sites and in fact could be compensatory. 
For example, patients with depression have been observed to have decreased number 
of 5HTT binding sites in peripheral blood cells, with that number increasing following 
antidepressant treatments, seemingly contradicting the Iga et al. study and the 
monoamine hypothesis (Pena et al., 2005). Finally, a genetic polymorphism in the 
promoter region of the 5HTT has been found with subjects carrying the short (s) allele 
being more susceptible to early life stress compared to the long (l) allele (Caspi et al., 
2003). Interestingly, PET imaging has shown that the depression-sensitive s allele was 
accompanied by a decreased number of 5HTT binding sites (Heinz et al., 2000).  
 
Norepinephrine and adrenergic receptors 
The catecholamine norepinephrine (NE) also displays imbalances in animal 




produced by neurons in the Locus Coeruleus and affects numerous brain regions. These 
include those regions involved in learning, memory, executive function, sleep regulation, 
and the stress response. It is not surprising then, that NE can play a pivotal role in 
depression (Goddard et al., 2010). DD are associated with low NE levels in blood and CSF 
and medications that deplete NE led to symptom resurgence in patients with remission 
(Ressler and Nemeroff, 2000; Goddard et al., 2010). NE plays an important role in 
mediating the stress response. In animal models of acute stress, there is an increase in 
NE release and activity with concomitant decrease in binding sites of the α2A-adrenergic 
receptor (α2AR), α1R, and β1. However, in chronic stress and postmortem tissue, in 
general, there are decreased NE activity and turnover, increased density and expression 
of α2a/c receptors, and increased density of β-adrenergic receptors (Pandey et al., 
1987; Ressler and Nemeroff, 2000; Morilak et al., 2005; Goddard et al., 2010). In a study 
examining platelet protein levels of α2AR receptor, it was found that patients with 
depression had elevated levels of α2AR, which decreased after treatment with the α2AR 
antagonist mirtazapine and that decreases correlated to improvement (Garcia-Sevilla et 
al., 2004). Antidepressants may also act on specific receptor subtypes. For example 
desipramine, an NE reuptake inhibitor which has antidepressant effects in both mice 
and rats under both normal conditions and chronic stress, appears to be mediated by 
functional α2A, but not β1 or β2, adrenergic receptors (Yalcin et al., 2005; Zhang et al., 
2009). Also, it was proposed that the α1R has an important role in the mechanism by 
which desipramine prevents cognitive dysfunction due to chronic stress (Bondi et al., 




chronic stress results in NE downregulation and increased α2AR (Goddard et al., 2010). 
This implies that examination of adrenergic gene expression could help to better 
understand specific and dynamic changes in NE processing in depressed patients. 
 
Dopamine 
There is also evidence for the important role of dopamine (DA) in depression. DA 
plays an important role in reward-seeking and motivation, the disruption of which can 
lead to anhedonia. Perona et al. found that knock-out (KO) mice lacking the dopamine 
transporter (DAT), responsible for soaking up free synaptic dopamine, displayed anti-
depressive like behavior in three separate tests (Perona et al., 2008). Conversely, 
decreased DAT binding has been observed in several human studies of depression, 
perhaps a consequence of chronic dopamine depletion, similar to changes seen with NE 
(Meyer et al., 2001b; Sarchiapone et al., 2006). Decreased mRNA for the dopamine 
receptor (DRD4) has been observed in lymphocytes from patients with MDD, followed 
by normalization after an 8-week treatment with the SSRI paroxetine (Stefanis et al., 
1998; Rocc et al., 2002; Xiang et al., 2008). Decreased DRD3 mRNA levels in peripheral 
cells have been found in patients with schizophrenia and bipolar disorder, and subtype-
specific changes in receptor expression have been observed in postmortem tissue in the 
amygdala (Stefanis et al., 1998; Klimek et al., 2002; Vogel et al., 2004; Xiang et al., 2008).  
These results suggest dysregulation of monoamine signaling for serotonin, 
dopamine, and norepinephrine in people with depressive disorders that may be related 




multiple receptors involved in monoamine signaling could help identify population 
subgroups and the development of patient-specific treatment strategies. 
 
HPA, glucocorticoids, and immune response 
 An early and reproducible finding in patients with depression is hyperactivity of 
the hypothalamic pituitary adrenal (HPA)-axis, as evidenced by high levels of the 
glucocorticoid cortisol in 50% of patients with depression and increased levels of stress 
hormones and pro-inflammatory cytokines (Nemeroff and Vale, 2005). The 
glucocorticoid receptor (GR) mediates cortisol negative feedback and regulating 
immune function following particular environmental stimuli. Normally sequestered in 
the cytoplasm, upon binding cortisol, the GR dimerizes, enters the nucleus, and binds to 
glucocorticoid response elements (GRE) to inhibit gene transcription, including acting on 
transcription factors (TF) such as the  nuclear factor kappa B (NFkB1) and the cyclic AMP 
response element binding protein (CREB1) (Anacker et al., 2011a). These TFs have 
numerous roles in growth, cell differentiation, and immune activation. Cortisol-induced 
inhibition of these TFs is beneficial during an acute stress response, but is likely 
detrimental in chronic situations where it results in heightened immune function and 
neuronal atrophy. Pro-inflammatory cytokines, such as interleukin-6 (IL-6), IL-1, 
interferon (IFN)-γ, and TNFα, which are all regulated by NFkB-1, have been shown to be 
elevated in DD in both serum and plasma (Dowlati et al., 2010; Shelton et al., 2011). 
Furthermore, increased cytokine mRNA is seen in healthy humans during chronic stress 




of cancer using IFN-γ, results in increases in cortisol pathway components and can lead 
to depressive symptoms comparable to those in subjects with DD that are otherwise 
medically healthy (Capuron et al., 2003; Capuron et al., 2009). In animal models, 
increases in pro-inflammatory cytokines are associated with depressive-like behaviors, 
which can  then  be ameliorated by antidepressants, receptor KOs, or cytokine-specific 
antibodies (Zunszain et al., 2012). Changes have also been observed for the 
glucocorticoid expression in animals and humans. For example, in mutant mice, 50% 
under-expression was pro-depressive, while over-expression was protective (Ridder et 
al., 2005). Also, Hageman et al. observed that GR mRNA expression was decreased in 
subfields of the hippocampus in animals exposed to chronic stress, which also led to 
depressive symptoms in the forced swim test, a model of learned helplessness. Both of 
these effects are reversed in stressed rats that receive electric convulsive stimulations 
(ECS). Interestingly, ECS displayed modest or no effect on nonstressed animals, which 
seems to indicate that ECS is only beneficial when righting imbalances (Hageman et al., 
2009). GR in humans is complicated by the existence of two isoforms: GRα, which is 
transcriptionally active, and GRβ, which is not. Matsubara et al. found that in patients 
with DD, levels of the transcriptionally active GRα (but not GRβ) were significantly 
reduced compared to controls, both during a depressive episode and in remission, 
which is potentially indicative of imbalance that leads to glucocorticoid dysfunction and 
elevated cortisol levels (Matsubara et al., 2006). Since cytokines and hormones have 




and cytokine expression could serve as biomarkers for depression and potentially be 
indicators of treatment response (Miller et al., 2009; Zunszain et al., 2011). 
 
Transcription and growth factors 
 Transcription factors, which are a necessary component for chromatin 
remodeling and consequently gene expression regulation, are also observed to display 
dysregulation in DD. One class of interest is the histone deacetylase class (HDAC), of 
which sirtuins are a subclass, which function to stabilize histone-DNA binding and are 
therefore responsible for preventing DNA lengthening and gene transcription. Covington 
et al. found decreases in postmortem HDAC2 protein as well as in an animal model of 
chronic stress using social defeat (Covington et al., 2009). Interestingly, treatment with 
an HDAC inhibitor led to antidepressant effects in the chronic stress model, but not in 
controls (Covington et al., 2009). Acute, but not chronic, treatment with an HDAC 
inhibitor can actually cause depressive effects in healthy mice (Gundersen and Blendy, 
2009). These results  parallel human studies in which patients in a depressive state 
exhibited differences in factors belonging to the HDAC/SIRT family, differences that 
were either mitigated or reversed in subjects in remission (Hobara et al., 2010; Abe et 
al., 2011b). CREB-1 has also garnered attention owing to its important role in a myriad 
of cellular and physiological functions. Though Iga et al. found higher levels of CREB-1 
mRNA in patients, while Lai et al. found no difference compared to controls, both 
groups found significant decrease in CREB-1 after 8 weeks of administration of an SSRI 




 Because patients with depression display neuronal atrophy, for instance in the 
hippocampus, research studies have examined the expression of several growth factors. 
Among these, Neuropeptide Y (NPY) was found to be increased following ECS, including 
in the axons and fibers of hippocampal cells (Ma et al., 2002). Roles for the vascular 
endothelial growth factor (VEGF) in antidepressant actions in animals as well as 
elevations in VEGF gene expression in depressed patients that normalize following 
treatment have also been observed (Iga et al., 2007b; Lee et al., 2009; Minelli et al., 
2011). NPY is a neuropeptide involved in the stress response that has been suggested to 
counteract the detrimental effects of CRF and be involved in depression (for a review 
see (Morales-Medina et al., 2010)). Specifically, NPY has been suggested to possess 
anxiolytic properties in animals and humans; it is downregulated following acute stress, 
increased following antidepressant treatment and repeated ECS, and decreased in CSF 
and brain tissue of individuals with some affective disorders (Kuromitsu et al., 2001; 
Heilig, 2004). Importantly, Otsuki et al. found that mRNA gene expression for several 
growth factors were state-dependent, with MDD subjects during a depressive state 
displaying dysregulation, and those in remission not (Otsuki et al., 2008). This highlights 
the importance of monitoring both gene expression and treatment response when 
attempting to develop promising biomarkers.  
 
Mitochondria and metabolism 
Because symptoms of depression include loss of energy and decreased 




In particular, the numbers of mitochondria and energy metabolites are decreased in 
brain regions of patients, such as the prefrontal cortex, a region important for executive 
function, including decision making and social behavior (Scaglia, 2010; Manji et al., 
2012). Differences have also been found in blood. For example, Beech et al. found using 
microarrays, that whole blood from depressed subjects with BPD had an over-
representation of electron transport chain (ETC) genes, with many ETC genes displaying 
increases compared to healthy controls. Conversely, several other studies have 
observed decreases in multiple genes involved in the ETC, in both blood and tissue from 
subjects with BPD (Sun et al., 2006; Klempan et al., 2009). These discrepancies may be 
due to the differences in the psychological state of the subjects. For example, in a study 
examining platelets from patients with schizophrenia, alterations in ETC complex I were 
found to be dependent on mental state (Dror et al., 2002). On the other hand, 
Naydenov et al. found no changes, or even decreases in gene expression involved in the 
mitochondrial respiratory chain, following glucose deprivation in cultured lymphocytes 
from BPD subjects in manic, remissive, or depressed states (Naydenov et al., 2007; 
Beech et al., 2010). It would be interesting to examine gene expression during these 
multiple psychological states since these likely represent distinct metabolic demands. 
   
Roles of certain ion channel roles in pain, fatigue, and depression 
In addition to the many pathways that have been implicated in DD, published 
results from our research group suggest that pathways that underlie the sensations of 




expression in neurological disorders, including fibromyalgia (FM) and  chronic fatigue 
syndrome (CFS) (Light et al., 2009; Light et al., 2012a). Implicated metabolite detecting 
receptors include those of the purinergic families (P2X ionotropic and P2Y 
metabotropic) that sense ATP metabolites, the transient vanilloid receptor (TRPV) 
involved in the detection of heat, acid, pressure, and osmolarity, and the acid-sensing 
ion channels (ASIC), important for sensing changes in concentration of cations. mRNA 
gene expression of several of these were found to be upregulated in subjects with FM at 
baseline, or following a moderate exercise task in patients with CFS (Light et al., 2009).  
Gene expression levels also correlated with sensations of task-induced mental and 
physical fatigue. Interestingly, numerous animal studies have implicated these receptors 
as also playing a role in depressive symptomatology. In the case of the ASIC1a receptor, 
ASIC1a KO mice or WT mice treated with ASIC1a inhibitors show antidepressant and 
anxiolytic behavior (Coryell et al., 2009; Dwyer et al., 2009). Stimulation of the P2Y1 
receptor has been shown to have anxiolytic effects, while P2X7 KO mice displayed 
antidepressant-like but not anxiolytic behavior (Kittner et al., 2003; Basso et al., 2009). 
In humans, it has been suggested that polymorphisms in P2X7 may predispose 
individuals to DD, though these findings have been disputed by some (Lucae et al., 2006; 
Green et al., 2009; Skaper et al., 2010). Finally, anticonvulsants and antidepressants are 
often prescribed for the treatment of neuropathic pain with positive results, suggesting 
common mechanisms. Given the overlap of function in fatigue, pain, anxiety, and 




expression for some of these receptors that may be dependent upon depressive states 
and comorbidities.  
 
Conclusion 
 The etiology of depression is still poorly understood, and given the heterogeneity 
of symptoms and relatively poor treatment response, depression is not a singular 
disease but rather a multifaceted group of disorders. It would be of great benefit to 
physicians and patients to find noninvasive diagnostic tests that would help in the 
development of patient-specific treatments. We hypothesize that depressive episodes 
are likely the result of chronic dysfunction with state-dependent imbalances. Since the 
inflammatory and immune responses are involved in depression, we suggest that 
peripheral markers in cells that mediate these pathways and are exposed to the same 
chemical milieu as brain cells can provide insight into the dynamic psycho-physiological 
state of an individual. Gene expression measurements using qPCR allow for hypothesis-
driven studies that can nevertheless include genes representing multiple biological 
pathways. As yet, there is no widely used diagnostic test, though several are being 
explored by other groups (Papakostas et al., 2011; Pajer et al., 2012). This dissertation 
will describe preliminary gene expression studies examining diverse pathways involved 
in depression, including: adrenergic, monoamine, mitochondrial, metabolic, HPA axis, 
ion channel, and inflammatory pathways (Table 1.1). Chapter 2 describes a small set of 
genes before and following treatment in a group of 23 medication-refractory depressed 
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 Adrenergic 
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VIPR2 










Cytokines IL-10, IL-6, TNFα, TNFβ 
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that examined the effects of anesthesia on depressive symptoms and cognitive function  
compared to ECT (included in the Appendix) (Weeks et al., 2013). We hypothesize that 
some "imbalances" between controls and depressed individuals found at Pretreatment 
may normalize following treatment and thus represent potential diagnostic markers 
that will allow one to monitor treatment efficacy. Chapter 3 will examine an expanded 
gene panel on an independent sample set of 42 patients and 38 controls. Depression 
severity and currently taken medications will also be examined for possible correlations 
with gene expression. Results from our study may reveal unique patterns of gene 
expression, thus fueling further research into novel mechanisms of depression as well as 
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 An extensive literature implicates immune dysregulation and Hypothalamic 
Pituitary Adrenal (HPA) axis dysfunction in depressive disorders (DD). Furthermore, 
response to medication may be related in part to its ability to normalize immune 
dysregulation. However, compromised immunity in medication-resistant patients is still 
poorly understood and to date there are no reliable immune biomarkers for DD. 
Because depression is a dynamic and state-dependent disease likely involving both 
peripheral and central mechanisms, mRNA gene expression, which reflects a 
combination of genetic and environmental factors, may be a means to uncover immune-
related pathophysiology. White blood cells (WBCs), the circulating immune cells, can be 
sampled repeatedly as clinical conditions of depression patients’ change. WBCs also 
express nearly all of the genes of interest for DD immune dysregulation. We used real-
time quantitative polymerase chain reaction (qPCR) to evaluate mRNA gene expression 
in DD patients during a depressive episode and following treatment-induced symptom 
improvement, for a panel of genes related to stress and immune function previously 
implicated in DD. Our results suggest that DD patients during a depressive episode 
display significant increases for the transcription factor NFκB1, immune cytokines 
interleukin IL-10 and IL-6, and the GABAA modulator Diazepam Binding Inhibitor (DBI), as 
well as decreases in the α2A- and β1-adrenergic receptors, and the serotonin receptor 
5HTR1D. Interestingly, most of these genes remained dysregulated following treatment 
and resultant symptom improvement. The glucocorticoid receptor NR3C1 and dopamine 





immediately following treatment (Post) but returned to pretreatment levels 4 weeks 
later (Follow-up). Only one gene, SULT1A1, normal at pretreatment, displayed persistent 
decreases at Follow-up. Medications did not alter these results. These results indicate 
trait-dependent immune dysregulation for at least some genes in medication-refractory 
patients with DD, which may underlie their poor response to medication. Future work 
should investigate potential novel treatment targets involving the genes reported here 
as well as potential biological mechanisms underlying disease in this subpopulation.  
 
Introduction 
“The disease of depression remains a great mystery. It has yielded its secrets to science 
far more reluctantly than many of the other major ills besetting us.”  
-William Styron (Darkness Visible: A memoir of madness. Vintage Books, New York, 
1992) 
 
 Depressive disorders (DD) are a rapidly growing burden on society, estimated to 
become the second leading cause of disability by 2020 (World Health Organization, 
2004). Depression is characterized by symptoms of anhedonia, fatigue, poor 
concentration, memory impairment, disruptions in appetite and sleep, and increased 
risk for suicide. Despite the prevalence of DD and intense medical research, current first-
line and second-line treatments (serotonin re-uptake and norepinephrine re-uptake 
inhibitors, aka SSRIs and NRIs) are still ineffective for 50% of patients, which clearly 
indicates disease heterogeneity (Trivedi et al., 2006).  
 In addition to the monoamine hypothesis, stress and immune function have 





Miller et al., 2009; Blume et al., 2011). Immune cell numbers and pro-inflammatory 
cytokines are increased and anti-inflammatory cytokines decreased in a substantial 
proportion of DD patients, suggesting inflammatory immune activation. On the other 
hand, in DD patients, proliferative responses of immune cells are blunted and chronic 
inflammation (presumed to increase risk of DD) (Bartolomucci and Leopardi, 2009) 
reduces immune responses to virus exposure, indicating immune suppression (Pike and 
Irwin, 2006; Blume et al., 2011; Messay et al., 2012). This paradoxical immune response 
is accompanied and possibly mediated by alterations in the Hypothalamic-Pituitary-
Adrenal (HPA) axis. In response to acute stress, the HPA axis normally serves to 
modulate the immune system via corticotropin releasing factor and the production and 
release of cortisol. Cortisol activates the glucocorticoid receptors (GRs), causing 
increases in blood glucose levels while suppressing inflammation (and inflammatory 
cytokine release), appetite, pleasure seeking, and reproductive drive. Normally, 
activation of GRs also reduces the production and further release of cortisol by negative 
feedback, resetting these processes to normal levels after the acute stress is over. 
However, 50% of DD patients display hyperactive HPA, which may result in prolonged 
manifestation of the above symptoms. Thus, DD may be the result of impaired negative 
feedback of the HPA axis, with cortisol unable to turn off GR signaling, thereby causing 
dysregulation of immune function and long-term symptoms (Anacker et al., 2011b).   
 Examining changes in HPA axis receptors and immune-related pathways using 
gene expression in immune cells is one method to study possible dysregulation in these 





circulate through all tissues including the brain and mediate the immune response, 
express mRNA for virtually all of the receptors and cytokines of interest. Conveniently, 
repeated blood samples can be obtained noninvasively as the patient’s clinical condition 
changes (Gladkevich et al., 2004; Liew et al., 2006; Sullivan et al., 2006; Le-Niculescu et 
al., 2008; Segman et al., 2010). Genomic DNA remains relatively stable throughout life 
though sections can be silenced by methylation or acetylation of specific histones. In 
contrast, transcription of DNA, which results in mRNA expression, is a highly dynamic 
and controlled process that combines genetic and environmental influences to respond 
to internal and external physiological changes. As such, levels of RNA for key pathway 
genes could provide an advantageous means to monitor changes that lead to the 
symptoms, if not the causes, of DD, and can be used to determine the molecular 
mechanisms that lead to improvement of DD following treatment (Iga et al., 2008). 
Previous results from both microarray and real-time quantitative polymerase chain 
reaction (qPCR) have demonstrated that peripheral blood cells display gene expression 
alterations in HPA axis and immune function genes (including pro- and anti-
inflammatory cytokines, the transcription factor NFκB1, and the glucocorticoid receptor 
NR3C1) following acute stress as well as in depressive disorders (Bierhaus et al., 2003; 
Brydon et al., 2005; Matsubara et al., 2006; Iga et al., 2008; Miller et al., 2008; Di Nicola 
et al., 2012; Menke et al., 2012). Furthermore, exploiting the ability of taking repeated 
blood samples, some studies have found that changes in gene expression were related 
to disease states (Lai et al., 2003; Iga et al., 2005; Matuzany-Ruban et al., 2005; Iga et al., 





 Patients with medication-refractory depression are of particular interest because 
they typically have more severe depressive symptoms, and immune dysregulation has 
been shown to be greater in those with more severe DD (Su et al., 2009; Bufalino et al., 
2012). They may also represent a more uniform subgroup of the heterogeneous 
population of patients with DD. In the present study, we used qPCR to compare mRNA 
from 14 immune-related genes on the full complement of WBCs obtained from healthy 
controls and from patients with medication-resistant DD, to test the hypothesis that 
expression of multiple immune cell genes are dysregulated in these patients during an 
active depressive episode (Pretreatment). A second blood sample was collected after 
remission of depressive symptoms due to 8-12 treatments with electroconvulsive 
therapy (ECT) or a novel alternative intervention involving 10 treatments of deep 
anesthesia with isoflurane (Posttreatment). Finally, a third sample was obtained 4 weeks 
after the end of treatment, when potential immediate effects of the interventions have 
passed, but depressive symptoms were still in remission (Follow-up). We hypothesized 
that 1) subjects in a depressive episode would display Pretreatment gene expression 
abnormalities compared to nondepressed controls, 2) some dysregulated genes would 
normalize with symptom improvement (state-dependent), and 3) other genes would 
remain abnormal despite remission of symptoms (trait-dependent) and may underlie 
the chronic disease state and vulnerability to relapse. Finally, since several prior studies 
had shown that certain medications can alter levels of cytokines or other immune 
markers (Sluzewska et al., 1995; Hernandez et al., 2008; Fornaro et al., 2011), we 





Materials and Methods 
 All methods were approved by the University of Utah IRB and all subjects gave 
written consent for all methods and procedures described below. 
 
Subjects 
 The Depression (DD) group included 25 individuals (12 females) in an active state 
of moderate to severe depression. 19 of these patients had a primary diagnosis of major 
depressive disorder (MDD) (9F/10M, mean age 41.7±2.4), and 6 of these patients were 
diagnosed with bipolar disorder (BPD) (3F/3M, mean age 41.0±7.0). Due to 
unsatisfactory response to three or more different antidepressant medication regimens, 
these patients were under consideration for an open-labeled study comparing the 
cognitive and antidepressant effects of an experimental treatment using deep isoflurane 
anesthesia (ISO) to electroconvulsive therapy (ECT) ((Weeks et al., 2013), submitted). 
Two patients dropped from the study leaving 15 patients who subsequently received 8-
12 treatments with ECT and 8 patients who received 10 treatments with ISO, as 
previously described (Langer et al., 1985; Langer et al., 1995; Weeks et al., 2013). 
Clinical assessment was carried out and blood samples were collected before the start 
of treatment (“Pretreatment”, n=23), 24 hours after the last treatment (“Post,” n=23), 
and again 4 weeks after treatment cessation (“Follow-up”, n=21). All DD patients were 
clinically assessed using the Hamilton Rating Scale for Depression (HRSD-24) 
administered by psychiatrists or trained personnel. To ascertain gene expression 





examine only those patients who displayed a greater than 30% decrease in HRSD-24 
from Pretreatment to Posttreatment, deemed “treatment responders.” 13/15 subjects 
receiving ECT and 6/8 patients receiving ISO met these criteria [responders mean ECT 
36.08 ± 1.75 Pretreatment to 9.30 ± 1.73 Posttreatment, p <0.001, mean ISO 25.50 ± 
1.50 to 7.17 ± 1.22, p <0.001]. Pretreatment depression scores for these 19 patients 
broken down by diagnosis were MDD (n=15) patients averaged 32.8 ± 1.7 (range 19-48), 
while the BPD patients (n=4) averaged 27.8 ± 2.1 (range 23-33). Controls (CON) included 
20 individuals with no current symptoms of depression (13 females, mean age 48.1 ± 
2.8). All participants were nonpregnant and between 24 and 67 years old. 
 Table 2.1 displays a summary of clinical parameters, including medications, for 
the 19 treatment responders who were used for all subsequent analysis.  Of the 19 DD 
patients, 12 were tested on an antidepressant including selective serotonin reuptake 
inhibitors (SSRIs), selective norepinephrine reuptake inhibitor (NRI) and/or mixed 
serotonin and norepinephrine reuptake inhibitors (SNRIs). Smaller numbers of DD 
patients were tested on lithium (n = 1) and nonlithium antipsychotic medications (n = 7). 
At Pretreatment several patients were also tested on anticonvulsants (n = 7). Of the 
remaining 11 patients, some had stopped these medications in anticipation of 
treatment (n = 4), a common clinical practice, since anticonvulsants can interfere with 
treatment efficacy. A subset of both group, comprising 17 CON and 3 DD, were tested 
on no psychotropic medication. Three of the currently nondepressed CON were also 
antidepressant medication as a covariate in order to ensure that mRNA differences were 





     Control   MDD   BPD DD (comb)  
   n=20  n=15  n=4 n=19 
Age(years)  48.1±2.8  40.9±2.8  33.8±8.3 39.4±2.8
a 
Gender(Male/Female) (7/13)  (8/7)  (2/2) (10/9) 
Treatment (ECT/ISO)     (11/4)  (2/2) (13/6) 
HRSD-Pretreatment     34.1±2.0  27.8±2.1 32.8±1.7 
HRSD-Post    9.4±1.3b  6.25±2.2b 8.7±1.2
b 
HRSD-Follow-up    13.9±2.0c  12.3±2.9c 13.6±1.7
c 
No medication  17  4  0 4 
Antidepressants  3  10  2 12 
Anticonvulsants/withdrawn  0  4/4  3/0 7/4 
SSRIs   3  3  1 4 
NRI  1  1  0 1 
SNRI  0  7  1 8 
TCA   0  0  0 0 
Opioid   0  1  0 1 
Antipsychotic   0   5  3 8 
aAge was significantly lower in DD compared to control group (Student’s t-test, p =0.03) 
bHRSD was significantly decreased at Posttreatment compared to Pretreatment (p<0.001) 
cHRSD was significantly decreased at Follow-up compared to Pretreatment (p<0.001) 
SSRI (selective serotonin reuptake inhibitor), SNRI (mixed serotonin-norepinephrine 
reuptake inhibitor), NRI (norepinephrine reuptake inhibitor), TCA (tricyclic antidepressant) 
Table 2.1 Demographic summary for Control and DD at baseline for treatment responders  
 
mRNA extraction and analysis 
 All blood processing and analyses were performed by personnel blinded to the 
subjects’ group. Blood was collected in EDTA tubes and kept on ice, and within 15 
minutes after collection, the blood was centrifuged at 3200 rpm (1315 x g- Clay Adams 
Compact II Centrifuge) for 12 minutes, plasma was removed, and the white layer 
carefully collected in RLT+β-ME (Qiagen, Valencia, CA), then quickly frozen using a 
methanol-dry ice slurry, and stored at -80ºC. RNA was extracted using RNeasy mini kits 





Immediately following extraction, RNA was converted to a cDNA library using the ABI 
High Capacity cDNA Archive Kit (Applied Biosystems/Life Technologies, Inc., Foster City, 
CA), followed by treatment with RNase-H (Epicentre Biotechnologies, Madison, WI). The 
cDNA samples were stored at -20o C until analysis. RNA integrity was assessed with a 
Bioanalyzer, and consistently found to have RIN values (RNA integrity numbers) greater 
than 9. The cycle counts for the control gene, TF2B, averaged 21.78 ±1.67 (SD) for 
control subjects and 22.32 ± 2.09 (SD) for patients, Student’s t-test p = 0.12. We 
selected TF2B as the preferred control gene and have verified that TF2B qPCR counts do 
not change in freshly harvested separated human leukocytes under a variety of 
conditions, when RNA is processed as described here.  
 The cDNA libraries were analyzed using the ABI quantitative, real-time PCR 
system on the ABI Prism 7900 Sequence Detection System (SDS) 2.4.1 (Applied 
Biosystems, Inc., Foster City, CA), using ABI TaqMan Master Mix (Applied Biosystems, 
Inc., Foster City, CA). Master Mix/primer plus primer/probe solutions and template 
solutions were separately loaded onto 96 well pre-plates. Then 384 well plates were 
robotically loaded and mixed from the 96 well plates. Each targeted gene was examined 
in duplicate, with TF2B standards being run in quadruplicate. Additional control samples 
containing no template were also run. Primer probes for the 24 genes were obtained 
from TaqMan Gene Expression Assays (Applied Biosystems, Inc., Foster City, CA), were 
as follows: Adrenergic A2A - Hs00265081_s1; Adrenergic B-1 - Hs02330048_s1; 
Adrenergic B-2 - Hs00240532_s1; Diazepam Binding Inhibitor - Hs00220950_m1; 





Hs01005217_m1; IL-10 -Hs00174086_m1; IL-6 - Hs00174131_m1; Neuropeptide Y NPY – 
Hs00173470_m1; Nuclear Factor Kappa B 1 – Hs00765730_m1; Serotonin Receptor 1D 
HTR1D –Hs00704742_s1; Sulfotransferase 1A1 - Hs00738644_m1; Toll Like Receptor 4 
TLR4 - Hs00152937_m1; Vascular Endothelial Growth Factor A - Hs99999070_m1; 
Control primer probe TF2B - Hs00155321_m1q. PCR data were processed using the 
SDS2 program from Applied Biosystems with count values for genes computed in the 
curve log-linear using a standard 0.2 threshold. Gene expression amounts were 
determined using the 2-ΔT method, where ΔT is the count difference of the candidate 
gene from TF2B. 
 
Statistics 
 All statistical tests were made with the SPSS ver. 19 statistical software. For the 
purposes of this exploratory study, we combined the MDD and BPD group into one 
depressed (DD) group. Potential gender effects were tested using nonparametric tests 
and found to be not significant (p > 0.05) for any comparisons and so males and females 
were combined into a single group for all remaining comparisons. Therefore, a single DD 
group was used for subsequent comparisons within group as well as with the CON 
group. Similarly, statistics were conducted to verify that no significant differences in 
gene expression were present in patients in the ECT vs. ISO group both before and after 
treatment (p > 0.1) and thus we combined these two treatment groups. Between-group 
comparisons were done using nonparametric Mann-Whitney U tests and within-group 





reports using qPCR (Iga et al., 2005; Belzeaux et al., 2010). Genes were further tested for 
correlations (Spearman) with other genes, as well as Pretreatment depression severity 
and changes following treatment response (expressed as the HRSD difference from Post 
or Follow-up and Pretreatment). Finally, within-and between-group comparisons 




Differentially expressed genes in DD compared to CON 
 The main goal of this study was to investigate possible immune cell gene 
expression dysregulation in subjects with DD during a depressive episode, as well as 
after symptom improvement, versus CON. To this end, we selected genes representing 
the stress and immune pathways: the glucocorticoid receptor, cytokines, adrenergic 
receptors, growth factors, transcription factors, and signaling modulators. Specifically, 
we were interested in three separate expression patterns: (i) “trait” genes, which 
display Pretreatment mRNA dysregulation that persists even after treatment and 
symptom improvement, (ii) “state” genes, which display Pretreatment mRNA 
dysregulation, but whose expression moves towards CON levels following treatment, 
and (iii) “treatment” genes, which display mRNA expression that is altered acutely at 
Posttreatment, but reverts to Pretreatment levels at Follow-up. As described in the  
methods section, because no differences were seen for gender, diagnosis, or treatment 





                   DD Pre vs. CON                        DD Post vs. CON                  DD Fol vs. CON 
GENE na FCb        pc n FC          p  n FC p value 
ADR2A 18 -2.49 0.001 15 -1.96 0.067 14 -1.79 0.046 
ADRB1 13 -3.51 0.055 15 -4.59 0.002 15 -3.99 0.023 
ADRB2 17 -1.08 0.715 12 -1.23 0.129 12 -1.02 0.785 
DBI 18  1.43 0.001 13  1.36 0.004 11  1.37 0.003 
DRD4 19 -1.03 1.000 16 -1.35 0.181 16 -1.09 0.464 
HTR1D 16 -2.72 0.046 11 -7.10 0.003 11 -5.95 0.007 
IL-10 18  2.27 0.014 13  1.70 0.210 11  2.48 0.201 
IL-6 18  1.65 0.019 4  dND ND 4 ND ND 
NFKB1 18  1.34 0.000 9   1.15 0.030 6 ND ND 
NPY 17 -1.03 0.885 12 -1.21   0.301 12 -1.00 0.988 
NR3C1 19 -1.15 0.431 13 -1.59 0.006 11 -1.28 0.160 
SULT1A1 17  1.02 0.976 11 -1.17 0.141 13 -1.20 0.043 
TLR4 16 -1.15 0.289 13 -1.04 0.792 12  -1.20 0.271 
VEGFA 18  1.04 0.907 16  1.12 0.390 16  1.05 0.656 
an sample size number b Fold change (FC) was calculated by the ratio Positive fold 
change upregulation (DD/CON) while negative fold change downregulation (-
CON/DD). c p value was calculated using Mann-Whitney U test. p<0.05 in bold and 
p<0.01 in italics d ND: gene was not tested for this time point since it had a sample 
size <8.  
 
 
 Before treatment, depressed subjects who later responded to treatment (as 
indicated by HRSD scores) differed significantly from CON in the expression of 7 immune 
cell genes (ADR2A, ADRB1, DBI, HTR1D, IL-10, IL-6, NFKB1). Between group and within 
group gene expression is shown in Table 2.2 and Table 2.3, respectively.  
 Trait genes. Four of these (ADR2A, ADRB1, DBI, and HTR1D) maintained their 
differences in mRNA expression both immediately Posttreatment and 4 weeks later at 
Follow-up, suggesting they are trait dependent genes.  Three of these (ADR2A, ADRB1, 
HTR1D) had decreased mRNA relative to controls and DBI mRNA was increased relative 
to controls at all-time points (Figure 2.1). 
 





 DD Post vs. Pre  DD Fol vs. Pre  
GENE na         FCb p valuec n         FC p value 
AD2A 15 1.15 0.609 14 1.39 0.084 
ADBR1 11 -1.31 0.477 13 -1.14 0.463 
ADBR2 12 -1.14 0.084 12 1.06 0.875 
DBI 13 -1.06 0.311 11 -1.05 0.929 
DRD4 16 -1.32 0.026 16 -1.07 0.679 
HTR1D 11 -2.61 0.075 11 -2.18 0.477 
IL-10 13 -1.33 0.075 11 1.10 0.374 
IL6 4 dND      ND  4 ND      ND  
NFKB1 9 -1.17 0.011 6 ND      ND  
NPY 12 -1.22 0.272 12 1.03 1.000 
NR3C1 13 -1.38 0.009 11 -1.11 0.929 
SULT1A1 12 -1.200 0.019 10 -1.23 0.059 
TLR4 12 1.12 0.638 12 -1.05 0.875 
VEGFA 15 1.07 0.570 15 1.00 0.609 
a n sample size number  
b Fold change was calculated by the ratio of gene expression means. Positive fold change 
corresponds to an upregulation at Posttreatment or Follow-up while negative fold change 
corresponds to downregulation. 
c p value was calculated using Wilcoxon paired test.  p<0.05 in bold and p<0.01 in italics  
d ND: gene was not tested for this time point since it had a sample size <8.  
 
 
























































































































Figure 2.1 Trait-dependent gene expression dysregulation. Adrenergic receptors 
ADR2A and ADRB1 are decreased during a depressive episode, and remain 
decreased following treatment. GABAA modulator DBI remains elevated before 
and after treatment, while serotonin receptor HTR1D has decreased levels. 
Expression levels are plotted on a log scale. CON are represented as diamonds 
on the left and individual DD patients are connected by lines for Pretreatment, 
Post-treatment, and Follow-up. Medians are represented by horizontal bars.  























































































































































 State genes. NFKB1 mRNA was higher relative to controls at Pretreatment (1.34 
fold higher), and was significantly decreased (p <.011) Posttreatment, though levels 
were still significantly higher than controls (p <.03) (Figure 2.2). Unfortunately, not 
enough data were collected at Follow-up to determine if the normalization towards 
controls was maintained at the Follow-up time-point. IL-10 mRNA was also higher than 
controls at Pretreatment, with some subjects displaying normalization following 
treatment at Posttreatment and Follow-up suggesting IL-10 may be a potential state 
gene. The immune cytokine IL-6 mRNA displayed significant Pretreatment increases 
compared to controls. We did not process enough samples to determine changes 
following treatment.  
 Treatment genes. We observed changes immediately Posttreatment for several 
genes that displayed no Pretreatment differences from CON. Within-group analysis 
indicated significant decreases immediately Posttreatment for NR3C1 (p <0.01), DRD4 (p 
= 0.01), and SULT1A1 (p = 0.02). At follow-up, DRD4 and NR3C1 had returned to 
Pretreatment levels, while SULT1A1 remained decreased compared to Pretreatment 
levels in DD (p = 0.04). Expression changes for these genes are shown in Figure 2.3. 
 To explore whether gene expression levels were related to symptom 
improvements, we computed Spearman correlations between Pretreatment gene 
expression and depression severity as well as with depression score evolution. None of 
the candidate genes were related to depression severity as assessed by HRSD, nor were 
they predictive of depression improvement. There were, however, several genes whose 































































































               
Figure 2.2 State-dependent gene expression dysregulation. NFκB1 and IL-10 are both 
elevated Pretreatment compared to CON but decrease Posttreatment towards CON 
levels. Expression levels are plotted on a log scale. CON are represented as diamonds on 
the left and individual DD patients are connected by lines for Pretreatment, 
Posttreatment, and Follow-up. Medians are represented by horizontal bars                                
*indicates difference between groups (* p<0.05, **p<0.01) using Mann Whitney U test.  








Figure 2.3 State-Treatment dependent genes that display comparable expression at baseline 
but dysregulation at Posttreatment or Follow-up. Expression levels are plotted on a log scale. 
NR3C1 and DRD4 show group decreases Posttreatment but return to Pretreatment levels at 
Follow-up. SULT1A shows group decreases at Posttreatment and Follow-up. CON are 
represented as diamonds on the left and individual DD patients are connected by lines for 
Pretreatment, Post, and Follow-up. Medians are represented by horizontal bars. * indicates 
difference between groups (* p<0.05, **p<0.01) using Mann Whitney U test.  # indicates 




































correlations for ADR2A/HTR1D (+0.529, p = 0.035), ADRB1 with ADRB2 (+0.706, p = 0.01) 
and with HTR1D (+0.601, p = 0.039), ADBR2 with DBI (+0.562, p =0.024) and with IL-10 
(+0.512, p = 0.045), and finally NFκB1 with NR3C1 (+0.649, p = 0.004).  
 
Effects of medication on gene expression 
 We examined the effect of several classes of medications on gene expression: 
serotonin/norepinephrine re-uptake inhibitor antidepressants (SSRIs, SNRIs, and NRIs), 
anticonvulsants, and antipsychotics. For antidepressants, removal of patients and 
controls on SSRIs (DD/CON n=4/n=3), NRI (1/1) or SNRIs (8/0) did not alter between-
group differences seen with their inclusion suggesting that reuptake inhibitors did not 
contribute to the mRNA differences seen in this study. 
 For anticonvulsants, at the Pretreatment blood draw, 4 patients had their 
anticonvulsants withheld in anticipation of ECT treatment, 7 were still taking them, and 
8 were never on anticonvulsants. No patients were on anticonvulsants at 
Posttreatment. Analysis revealed that DD patients not on anticonvulsants maintained all 
mRNA differences observed in the entire population of patients. Thus, anticonvulsant 
use did not substantially contribute to the mRNA differences obtained between DD and 
CON groups. In fact, within-group comparisons for those patients on anticonvulsants 
versus those without at Pretreatment displayed trends for lower gene expression in IL-6 
(p = 0.076), NFKB1 (p= 0.076), and NR3C1 (p = 0.083), suggesting possible 
immunosuppresive effects of these medications that normalize gene expression 





 Patients not on antipsychotics maintained mRNA differences for all genes that 
differed between groups. Within-group analysis for those on antipsychotics compared 
to those without, however, demonstrated decreased mRNA gene expression for 
subjects on antipsychotics for IL-10 (p = 0.013), IL-6 (p = 0.013), NFκB1 (p = 0.051), and 
NR3C1 (p = 0.008). Similar to anticonvulsants, because these medication effects are in 
the opposite direction of our DD group differences, it is possible that increases in the 
expression of these mRNAs among the DD patients compared to controls would have 
been even greater if antipsychotics had been stopped in all patients. This seems to 
indicate that partial normalization of immune function may be one of the benefits of 
these drug classes in DD patients. 
 
Discussion 
 There were three principal findings in the present study: 
 1) During the Pretreatment depressive state, patients with medication-refractory DD 
exhibited dysregulated gene expression in immune, HPA axis, and monoamine signaling genes. 
These alterations included decreased expression of adrenergic receptors ADR2A and ADRB1 and 
the serotonin receptor HTR1D, elevated pro- and anti-inflammatory cytokines (IL-6 and IL-10 
respectively), and elevated immune transcriptional regulator NFκB1 and neurotransmission 
modulator DBI. These genes have known roles in stress regulation and their dysfunction may 
contribute to DD symptoms.  
 2) Dysregulated genes displayed trait, state, and treatment-dependent expression 
patterns following treatment-induced symptom improvement. Trait related genes, DBI (higher 





were lower than controls at all sampled time points) were not significantly altered by treatment 
and/or symptom improvement, as would be expected in genes related to traits. State-related 
genes, NFκB1 and IL-10, had gene expression higher than CON Pretreatment and expression 
levels shifted toward control levels immediately Posttreatment.  Thus, these genes may be 
related to the state that is DD, which is improved by treatment. Treatment-related genes, DRD4, 
NR3C1, and SULT1A1, had mRNA levels that were not different from controls at Pretreatment. 
However, the expression of these three genes decreased following treatment.  DRD4 and NR3C1 
returned to the Pretreatment levels at the Follow-up time-point, but SULT1A1 remained 
decreased at Follow-up.  These results suggest that despite symptom improvement, these 
patients continue to display immune dysregulation, which may underlie their poor response to 
medication and their increased likelihood of disease relapse.  
 3) Concurrent use of antipsychotic and anticonvulsant medications does not promote, 
and in fact may partially mask, leukocyte gene expression differences. Within-group analysis 
found that subjects on these medications displayed decreases in mRNA for IL-10, IL-6, NFκB1, 
and NR3C1 bolstering the notion that medications may confound the search for RNA 
biomarkers. We did not observe any masking effects of antidepressants.  
These major findings are further discussed below.   
 
Cytokines and NFkB1 are elevated pretreatment during depressive episodes 
Gene expression for the cytokines IL-10 and IL-6 were elevated at Pretreatment. 
Cytokines are important signaling molecules produced by brain and immune cells to induce 
inflammation in response to stress and foreign pathogens. IL-10, which primarily plays an anti-
inflammatory role, has been found to have elevated mRNA levels in patients during a depressive 





IL-10 do not differ between patients with depression and controls (Dowlati et al., 2010). IL-6, 
which has diverse roles, including roles in depression, cancer, and asthma (Scheller and Rose-
John, 2006), has been shown to have both elevated protein and mRNA levels in depression (Tsao 
et al., 2006; Dowlati et al., 2010) and acute increases following stressful mental tasks (Brydon et 
al., 2005). The combined dysregulation of both a pro- and an anti-inflammatory marker (IL-6 and 
IL-10 respectively) suggests immune imbalance consistent with observations of both immune 
activation and suppression in depressive disorders, though the functional net effect is still poorly 
understood (Blume et al., 2011). Interestingly, in depression patients we also observed elevated 
gene expression for the transcription factor NFkB1 that regulates cytokines and has an 
important role in mediating HPA axis stress immune response. Though only few studies have 
examined NFkB1 gene expression, NFkB1 binding activity has been found to be elevated 
following acute psychosocial stress in humans and animal model (Bierhaus et al., 2003) and 
upregulation of target genes was observed in family caregivers of brain cancer patients (Miller 
et al., 2008). Therefore, higher levels of NFkB1 could lead to imbalance in cytokine expression 
and chronic inflammatory response.  
 
Adrenergic receptor gene expression for ADR2A and ADRB1, 
but not ADRB2, are downregulated 
Catecholamines and their receptors have been shown to have key roles in the stress and 
immune response in both animal models and humans (Ressler and Nemeroff, 2000; Morilak et 
al., 2005; Levy and Tasker, 2012). We found that mRNA gene expression for ADR2A and ADRB1 
(but not ADRB2) adrenergic receptors were decreased in depressed patients versus controls. 
This is in contrast to results of human and animal studies that have examined protein levels and 





the ADR2A receptor protein and binding sites (Callado et al., 1998; Ordway et al., 2003; Garcia-
Sevilla et al., 2004; Valdizan et al., 2010), though some studies suggest no change or even a 
decrease in binding (Maes et al., 1999; Marazziti et al., 2001). Differences may be a result of 
depression severity and individual disease history. In rodents, for example, acute stress was 
associated with an increase in NE release and activity, and with a decrease in adrenergic 
receptor proteins including ADR2A, ADRB1, and ADRB2 (Goddard et al., 2010). Conversely, 
chronic psychosocial stress results in hypo-NE activity with decreased NE release, increased 
ADR2A receptors binding sites, increased density of ADRB-adrenergic receptors, and changes in 
NE turnover and availability (Ressler and Nemeroff, 2000; Goddard et al., 2010). In humans, the 
ratio of ADR2A and ADRB1 binding sites has been suggested to relate to suicidality (Sastre et al., 
2001), and we found a significant correlation between ADR2A and ADRB1 receptors at 
Pretreatment, which suggests that diagnostic markers may benefit from examination of multiple 
components of the adrenergic system. We did not see any difference in ADRB2 consistent with 
previous study by Jeanningros et al. examining ADRB2 receptor density, though they found 
significant decreases when examining only unipolar depression and receptor density correlated 
with depression severity (Jeanningros et al., 1991). Together, these results suggest that 
adrenergic receptors display dysfunction in MDD that may be related to depressive state and 
type.  
 
Serotonin 1D receptor (HTR1D) gene expression is downregulated in 
refractory depression 
Serotonin plays a number of important roles in the immune system, among them 
macrophage phagocytosis, T cell proliferation and function, and cell attraction to sites of 





pro- and anti-inflammatory cytokines. Decreased expression of serotonin receptors may result 
in impaired ability to mediate important immune functions. However, it must be noted that 
decreases in mRNA gene expression does not necessarily mean decreases in receptor protein. In 
fact, changes in gene expression may be in response to the presence of increased membrane 
receptors or, conversely, low levels of serotonin could lead to understimulation of serotonin 
receptors and downregulation. We chose the HTR1D receptor subtype since we had previously 
shown that it is expressed on WBCs. We found that HTR1D gene expression was significantly 
decreased during a depressive episode, which with lower levels of serotonin availability may 
contribute to depressive symptoms. Though HTR1D was investigated in relation to the 
treatment of migraines, few studies have examined HTR1D in depression, and some reached 
contradictory conclusions, including both decreased and increased HTR1D binding depending on 
brain region and medication use (Arranz et al., 1994; Lowther et al., 1997). Conversely, the 
serotonin transporter (5HTT), which is responsible for reuptake of synaptic serotonin, has been 
found to be elevated in patients during a depressive episode, which in conjunction with 
decreased HTR1D receptor expression would greatly decrease serotonin signaling  (Iga et al., 
2005). 
 
Diazepam Binding Inhibitor (DBI) is upregulated during a depressive episode 
In our gene panel we included the Diazepam Binding Inhibitor (DBI), a gene which 
encodes a peptide that is a negative allosteric modulator of GABAA receptors with implicated 
roles in depression and anxiety (Corda et al., 1984; Barbaccia et al., 1986; Tsao et al., 2006). We 
found DBI mRNA levels to be significantly increased in the DD group at Pretreatment. This is in 
line with previous studies that found increased levels of DBI protein in CSF of drug-free 





was found for DBI levels and those of CRH in depressed patients, gamblers, and controls (Roy et 
al., 1989). Since GABAA receptors inhibit CRH producing cells, it is possible that elevated levels of 
DBI lead to increased levels of CRH and ultimately elevated cortisol, a common signature of HPA 
dysfunction found in many patients with depression (Ferrarese et al., 1993; Levy and Tasker, 
2012). Finally, DBI fragment has also been found to decrease the effect of benzodiazepines on 
pro-inflammatory cytokines following immune challenge, suggesting that increased levels of DBI 
may interfere with the efficacy of benzodiazepines for anxiolytic action and in HPA regulation 
(Taupin et al., 1991) and may therefore be a potential marker for treatment-refractory 
depression or anxiety. 
 
ADR2A, ADRB1, HTR1D, and DBI display trait-dependent expression 
We found that ADR2A and ADRB1 which were significantly decreased at Pretreatment 
and remained low relative to CON both immediately following treatment (Post) and 4 weeks 
later (Follow-up), suggesting trait dysregulation. Furthermore, these two receptors displayed a 
significant positive correlation at both Pretreatment and Posttreatment. However, a lack of 
significant change in gene expression does not mean a lack of change in protein or function. One 
published report on humans and several on rodents suggest that multiple sessions of 
electroconvulsive therapy leads to a reduction in adrenergic receptor density (Hosoda and 
Duman, 1993; Werstiuk et al., 1996; Seo et al., 1999). Therefore, our results in conjunction with 
published reports seem to imply that ECT helps with depressive symptoms in part by modulating 
adrenergic function, but trait imbalances persist and perhaps contribute to later depression 
relapse. Since norepinephrine and adrenergic function is part of the HPA axis, patients with 





results, adrenergic receptor gene expression may be a trait marker for depression, but is not 
predictive of treatment response.  
We found that despite symptom improvement, HTR1D mRNA levels remained low 
compared to CON at both Posttreatment and Follow-up suggesting trait-dependent gene 
expression, and thus that patients with severe refractory depression have persistent underlying 
physiological imbalances in this receptor subtype. Unlike HTR1D, other serotonin receptor 
subtypes and the serotonin transporter do display changes following treatment. For example, 
Belzeaux et al. observed significant within-group increases in HTR1B and HTR2A mRNA gene 
expression in WBCs at 8 weeks following treatments and symptom improvement, while several 
groups have observed decreased neuronal receptor binding following ECT or antidepressants as 
assessed by neural imaging (Yatham et al., 1999; Meyer et al., 2001a; Mischoulon et al., 2002; 
Belzeaux et al., 2010; Yatham et al., 2012). Gene expression alterations have been observed for 
the serotonin transporter 5HTT, namely, increased expression relative to controls at 
pretreatment during a depressive episode that decreased after 8 or 12 weeks of chronic 
treatment with specific SSRIs (Iga et al., 2005; Tsao et al., 2006). These results suggest 
dysregulation in serotonin signaling that is nevertheless receptor-type and function specific.  
Gene expression for the GABAA modulator DBI remained elevated at Posttreatment and 
Follow-up time points, suggesting that DBI levels were not confined to depressive episodes and 
could be a potential trait-dependent biomarker. This is in agreement with previous studies that 
found a lack of correlation between DBI peptide levels in the CSF and behavioral assessments, 
such as anxiety and depression severity, in depressed subjects (Barbaccia et al., 1986; Barbaccia, 
2011). Because DBI inhibition of GABAA receptors can lead to increased CRH, chronic elevation in 
DBI despite symptom improvement may potentially lead to persistent HPA dysregulation and 





IL-10, IL-6, and NFκB1 show state-dependent expression patterns 
We found that although significantly elevated at Pretreatment, IL-10 was no longer 
significant compared to controls following treatment and symptom improvement, which seems 
to indicate that IL-10 is a state-dependent marker. This would be consistent with previous 
findings of decreased IL-10 at 8 weeks following treatment, though ECT has been observed to 
result in an increase in stimulated IL-10 cytokine release (Belzeaux et al., 2010; Fluitman et al., 
2011). However, in our dataset, IL-10 gene expression displayed increased variability following 
treatment, with patients displaying both trait-like and state-like expression patterns. Larger 
sample sizes are needed to address this tentative finding. Future research should also address 
differences that may exist between patient responders and nonresponders, as well as patient-
specific changes in IL-10 in relation to other immune markers.  
We were unable to follow IL-6 over time because of insufficient sample size. However, 
previous work has suggested that IL-6 protein serum levels normalize following the use of 
antidepressants, though there were differences between responders and nonresponders 
(Sluzewska et al., 1995; Lanquillon et al., 2000; Kenis and Maes, 2002; Fornaro et al., 2011). 
Conversely, ECT has been found to result in increased IL-6 production following LPS stimulation 
(Fluitman et al., 2011). Future studies with a larger sample size will be able to identify IL-6 gene 
expression changes following treatment in medication-refractory depression.  
Though NFκB1 was significantly elevated in DD patients at both Pretreatment and 
Posttreatment compared to CON, it displayed within-group decreases following treatment, 
which is perhaps indicative of normalization and therefore of NFκB1 being a potential state-
dependent biomarker. Since acute levels of stress lead to an increase in levels and signaling of 





et al., 2003; Pace et al., 2006). Examination of treatment nonresponders with persistent 
depressive symptoms could be informative.  
 
NR3C1, DRD4, and SULT1A1 show treatment-dependent expression patterns 
The glucocorticoid receptor (GR), which is encoded by the NR3C1 gene, has been found 
to be dysregulated in depression patients (Miller et al., 2009; Anacker et al., 2011a). Though 
comparable to controls at Pretreatment, we found that NR3C1 gene expression displayed 
significant Posttreatment decreases in both between- and within-group analysis, but returned to 
Pretreatment levels at Follow-up. This seems to indicate that ECT and ISO treatments resulted in 
acute gene expression changes that were not related to symptom improvement at Follow-up. 
Similarly, Matsubara et al. found that gene expression for the GRα isoform was not related to 
prolonged symptom remission in patients with depression, but contrary to our results, they 
found that DD subjects had significantly decreased Pretreatment expression (Matsubara et al., 
2006). It is possible that concurrent medications contributed to the Pretreatment differences 
between our results and their study, as discussed in a section below. Finally, work by Hageman 
et al. in animals found that chronic stress reduced hippocampal GR mRNA, which then was 
restored with electroconvulsive shock (ECS), the animal equivalent of ECT (Hageman et al., 
2009). This is an example of an acute effect of treatment, though GR expression following 
cessation of chronic stress was not examined. It must be mentioned that dysregulation of NFκB1 
and GR has widespread implications, given the many physiological pathways they regulate. In 
microarray studies, stress in caregivers and fatigue in breast cancer survivors were associated 
with an over-representation of genes regulated by NFκB1 and decreased levels of NR3C1 target 
genes (Miller et al., 2008; Bower et al., 2011). In our studies, levels of NFkB1 and NR3C1 were 





0.419) though both genes decreased following treatment, which seems to suggest that ECT may 
affect these two genes differently. Because acute ECT has been shown to increase cytokines, 
ACTH, and cortisol in humans (Weizman et al., 1987; Kronfol et al., 1991; Fluitman et al., 2011), 
it is possible that the acute decreases in NFkB1 and NR3C1 are an effort to reestablish proper 
immune balance. Future studies should compare difference in these genes between treatment-
responders and nonresponders in order to determine if Pretreatment dysregulation could be 
predictive of treatment response, especially prior to an invasive treatment such as ECT. 
In our study, SULT1A1 displayed Pretreatment levels similar to those in healthy controls 
but had significant decreases Posttreatment that were maintained at Follow-up. SULT1A1 is 
responsible for the inactivation and ultimate metabolism of a number of compounds, including 
hormones, catecholamines, and drugs (Coughtrie, 2002). Thus, decreases in SULT1A1 mRNA and 
the enzyme product may lead to increased availability of these important signaling molecules 
and medications. Though research has shown that genetic variants of SULT1A1 can increase risk 
of breast or colorectal cancer, few studies have found differences in depressive disorders 
(Coughtrie, 2002; Pasqualini, 2009). One study by Marazziti et al. found variability in platelet 
protein levels of phenosulfotransferase (PST) (coded by SULT1A1) dependent upon mood 
disorder subtypes, namely, increases in obsessive compulsive disorder and patients with mania, 
decreases in patients with MDD or migraine, and no differences with BPD relative to controls 
(Marazziti et al., 1996). Future studies should examine medication-responsive patients to 
determine whether SULT1A1 may be an important contributor to symptoms in DD. 
The dopamine receptor DRD4 showed expression levels comparable to controls at all 
sampled time points tested both before and following symptom improvement, but displayed a 
significant within-group decrease at Posttreatment. This acute change may suggest an effect on 





the body related to symptom improvement. This is potentially important, given that dopamine 
mediates some bidirectional communication between the central and immune function (Basu 
and Dasgupta, 2000). This is in contrast to a study that found low Pretreatment DRD4 mRNA 
levels that normalized to controls following treatment with paroxetine (Rocc et al., 2002), or the 
elevated DRD4 observed in postmortem tissue from MDD and schizophrenia patients (Stefanis 
et al., 1998; Xiang et al., 2008). Variations in peripheral and postmortem levels of DRD3 and 
dopamine transporter have also been observed, suggesting dysregulation in depressive 
disorders (Meyer et al., 2001b; Vogel et al., 2004) 
 
Medications display immunosuppressive effects on gene expression 
There is an extensive literature on the effects of medications on immune function, 
including those of multiple classes of antidepressants, mood stabilizers, and antipsychotics 
(Kenis and Maes, 2002; Drzyzga et al., 2006; Sullivan et al., 2006; Choi et al., 2009; Miller et al., 
2009; Fornaro et al., 2011; Antonioli et al., 2012). This may help explain why in a panel 40 
candidate genes previously implicated in depression, only IL-10 was found to be significantly 
different from controls in a depressed population currently on benzodiazepines and 
antipsychotic medication (Belzeaux et al., 2010). In our study, we found that patients taking 
anticonvulsants and antipsychotics had decreased gene expression for several immune genes, 
specifically IL-10, IL-6, NFκB1, which were elevated in the DD group. This is consistent with an 
immunosuppressive role for these medications that has been suggested to underlie their 
beneficial effects (Piazza et al., 1996; Pollmacher et al., 2000; Drzyzga et al., 2006; Himmerich et 
al., 2011). We also found that patients taking these medications had lower NR3C1 glucocorticoid 
receptor gene expression compared to patients not on medications, though there were no 





medications may explain why we saw no GR differences at Pretreatment, whereas Matsubara et 
al. observed trait-like decreased GRα during depressed state as well as during remission 
(Matsubara et al., 2006). The effects of SSRI and SNRI antidepressants on cytokines and immune 
function must also be considered. Hernandez and colleagues observed that chronic use of SSRI 
decreased levels of anti-inflammatory cytokines and increased pro-inflammatory cytokines over 
the period of one year, while increasing the number of natural killer cells and B-cells in the 
WBCs (Hernandez et al., 2008; Hernandez et al., 2010). Results on the effects of medications on 
IL-6 have been mixed, with reports of increased, decreased, or no change in IL-6 serum levels in 
treatment responders (Sluzewska et al., 1995; Yoshimura et al., 2009; Fornaro et al., 2011). Tsao 
et al. found that SSRI treatment normalized elevated IFN-γ and 5HTT (Tsao et al., 2006). It must 
be noted, however, that Simon et al. observed increases in multiple pro- and anti-inflammatory 
cytokines in the serum (including IL-6, IL-8 and IL-10) in medication-naïve as well as medicated 
patients with MDD (Simon et al., 2008). Because our studies were done with medication-
refractory patients who nevertheless responded to ECT, it is possible that gene expression 
differences may be masked by immunosuppressive effects of medication. In the development of 
biomarkers, consideration of possible medication confounders will be crucial, since they may 
mask the dysregulated gene expression in depressive disorders.   
 
Study limitations 
 There are several limitations to this study that need to be considered in future 
research. First, this study examined patients with severe, treatment-resistant 
depression who have failed conventional treatments, while many of the studies 
referenced here studied patients during depressive states and following successful 





examine a unique and more severe subtype, our results cannot be generalized to all DD. 
There are likely to be many subtypes of depression with different gene expression 
patterns depending on current depressive states and treatments. Compilation of 
multiple gene expression studies may reveal patient subgroups that would otherwise be 
lost in smaller individual samples (Kenis and Maes, 2002). 
 Another consideration is the influence of medications on gene expression. 
Antidepressants, anticonvulsants, and antipsychotics are all known to lead to changes in 
protein and mRNA levels (Kenis and Maes, 2002; Drzyzga et al., 2006; Choi et al., 2009; 
Girgenti et al., 2010; Antonioli et al., 2012). Since only three controls were on 
antidepressants, while 14/19 of patients were taking such medications, we cannot rule 
out the possibility that the observed differences in gene expression are a result of drugs 
alone. However, the observation that gene expression differences between DD and CON 
groups persisted after excluding patients on various types of medications, and that use 
of antipsychotics and anticonvulsants appeared to minimize rather than contribute to 
these differences, strongly suggest that this is not the case. Lastly, this was a hypothesis-
driven pilot study that had a small sample size and a modest set of 14 candidate genes. 
We are currently evaluating a much larger sample with an expanded gene panel that 
elaborates upon immune genes and also includes other growth and transcription 









 We report here on findings of significant differences in mRNA gene expression in 
the HPA axis and immune function in subjects with medication-refractory depression. 
Specifically, we found changes in the glucocorticoid receptor, cytokines IL-10 and IL-6, 
adrenergic receptors ADR2A and ADRB1, serotonin and dopamine receptors, the 
transcription factor NFκB1, and the NT/ hormone modulators DBI and SULT1A1. In more 
detail, we found state-dependent dysregulation in NFκB1 and IL-10, which decreased 
following treatment and symptom improvement, showing trends towards control levels. 
We also found trait-like imbalances in noradrenergic receptors, serotonin receptor, as 
well as DBI, which suggest underlying chronic HPA dysregulation despite symptom 
improvement. We also identified several genes displaying acute expression changes 
Posttreatment that returned to Pretreatment levels at Follow-up, including the 
dopamine and glucocorticoid receptors. These may be related to the mechanisms of 
action of ECT and ISO treatment and merit further investigation. Overall, these results 
provide evidence of biological dysregulation detectable in blood from depressed 
patients who benefited from treatment. Future studies will expand upon genes involved 
in these pathways, and with a larger sample size will permit analyses comparing 
responders and nonresponders, a first step towards the development of patient-specific 
treatments based on objective blood biomarkers. 
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Depressive Disorders (DD) are a great financial and social burden and yet more 
than 30% of patients do not respond to conventional medications. These medication-
refractory patients present a unique group to discover possible mechanisms of 
depression. Here we identify several differences in gene expression between DD 
patients and age-matched controls in physiological pathways that have previously been 
implicated in the symptoms of depression. We used real-time quantitative polymerase 
chain reaction (qPCR) to evaluate mRNA gene expression from peripheral blood 
leukocytes for a panel of candidate genes, including a number of genes previously 
implicated in depression, as well as ones that may be related to co-morbid symptoms 
such as pain and fatigue. In our study, we included 42 currently depressed patients, 
specifically, 25 patients with major depressive disorder (MDD) and 17 patients with 
bipolar disorder (BPD), and a control group of 38 healthy, nondepressed controls. Out of 
a panel of 46 genes, we identified gender-specific mRNA gene expression dysregulation 
in APP, IL-10, IL-6, NRG1, OXTR, P2X7, P2Y1, and TRPV1, in females and ADRB2, ASIC3, 
and DBI in males. Concurrent medication use may have effected gene expression for 
NRG1, ASIC3, and TRPV1. These results help to confirm known immune dysregulation in 
depression as well as gene expression evidence for novel genes, including amyloid 
precursor protein and various ion channels involved in pain and fatigue. These gene 
expression differences could potentially be used to explore biological mechanisms of 







Depressive disorders (DD) are a devastating spectrum of diseases. including 
major depressive disorder (MDD) and Bipolar Disorder (BPD), which have a lifetime 
prevalence of 16.6% and 3.9%, respectively (Kessler et al., 2005). Women have a 70% 
higher risk for mood disorders compared to men (Kessler et al., 2005). Up to 30% of 
MDD patients have treatment-resistant or refractory depression that does not remit 
with currently available medications (Trivedi et al., 2006). Given that response to 
subsequent antidepressant medications drops precipitously with each medication 
failure, finding blood-based biomarkers to identify specific physiological pathways that 
are dysregulated in refractory depression would be of great potential help in identifying 
new drug targets and patient-specific treatments (Perlis, 2011). 
One promising source for biomarkers is leukocyte gene expression (mRNA), since 
mRNA measures reflect integration of genetic, epigenetic, and environmental effects 
(Iga et al., 2008). Furthermore, given the interconnections between the circulating 
immune system and brain function, evaluation of blood leukocyte mRNA allows for a 
simple, noninvasive approach to measure some features of an individual’s current 
neurophysiological state (Gladkevich et al., 2004; Sullivan et al., 2006). Previous 
research on associations between depression and leukocyte mRNA using real-time 
quantitative polymerase chain reaction (qPCR), including our own, has primarily 
evaluated one to two genes or an array of genes sharing the same functional class. 
These have included genes involved in monoamine signaling and the Hypothalamic-





Padmos et al., 2008; Iacob et al., 2013), or genetic transcription and cellular regulation, 
including histone deacetylase (HDAC) (Iga et al., 2007a; Hobara et al., 2010), sirtuin 
deacetylases (SIRT, another class in the HDAC family) (Abe et al., 2011b), cAMP response 
binding protein 1 (CREB-1) (Iga et al., 2007a) and vascular endothelial growth factor 
(VEGFA) (Iga et al., 2007b). In contrast to this approach of examining genes individually 
or by class, Belzeaux et al. compared mRNAs of 40 promising candidate genes linked to 
multiple biological pathways in 11 MDD patients and 11 matched controls. Of these 40 
genes, however, only interleukin 10 (IL-10), an anti-inflammatory cytokine involved in 
the immune response, was significantly higher in the MDD vs. the control group 
(Belzeaux et al., 2010). Because DD is a heterogeneous disorder, it is logical to 
hypothesize that the dysregulated pathways, and thus gene expression for those 
pathways, may differ in different patient subgroups including related to gender, 
diagnosis, and current medications.  
In the present exploratory study, we examined gene expression dysregulation in 
patients with medication-refractory DD during a moderate to severe depressive 
episode; they represent the subgroup of DD patients who are most difficult to treat, and 
for whom other pathways besides the serotonergic and noradrenergic systems, the 
target of most currently available medications, may underlie the disorder (Berlim et al., 
2008). In view of the large gender difference in DD prevalence, it also was deemed 
logical to examine mRNA alterations in male and female DD patients separately. Our 
gene expression panel was designed to evaluate 46 mRNAs from multiple diverse 





the remaining have been implicated in other disorders that have overlapping symptoms, 
including schizophrenia, Alzheimer’s disease, Chronic Fatigue and Fibromyalgia 
syndromes. These genes and their functional class are listed in Table 3.1.  
They include genes related to monoaminergic signaling, in particular receptors 
for serotonin, dopamine, and norepinephrine (Moret and Briley, 2000; Vogel et al., 
2004; Goddard et al., 2010; Albert et al., 2011; Iacob et al., 2013); the glucocorticoid 
receptors NR3C1 and NR3C2, both of which are involved in many of the functions of the 
HPA-axis (Anacker et al., 2011a); and a variety of immune cytokines and receptors to 
represent the inflammatory and immune response, which have also been implicated in 
depression (Miller et al., 2009). 
Our research group and others have observed changes in adrenergic gene 
expression and function; for this reason we also evaluated gene expression of several 
subtypes, including ADR2A, ADR2C, ADRB1, and ADRB2 (Jeanningros et al., 1991; 
Marazziti et al., 2001; Ordway et al., 2003; Valdizan et al., 2010; Iacob et al., 2013). We 
also included growth factors, transcription factors, and modulators with previous 
association with depression, including CREB1 (Iga et al., 2007a), DBI (Barbaccia et al., 
1986), SIRT1 and VEGFA (Iga et al., 2007c; Kishi et al., 2010; Abe et al., 2011a), and the 
VEGF receptor (VEGFR), the nuclear factor of kappa gene enhancer in B cells 1 (NFKB1) 
(Bierhaus et al., 2003), superoxide dismutase 2 (SOD2) (Selek et al., 2008) and 
sulfotransferase family cytosolic 1a (SULT1A1) that is involved in catecholamine 
processing (Marazziti et al., 1996). Also potentially important are genes coding for 





Pathways Classes Genes 
Monoamine 
and peptides 
Serotonin, dopamine HTR1d, DRD4  
 Adrenergic receptors ADR2A,ADR2C,ADRB1, ADRB2   
 peptides COMT, PSMA4, SULT1A1, 
VIPR2 










Cytokines IL-10, IL-6, TNFα, TNFβ 
 Antigen receptors, 
chemokine, TF 
TLR4, CXCR4, GZMA 




P2X1, P2X4, P2X7, P2Y1, P2Y2 






Chain + others 
ATP5E, COX5B, NDUFS5, 
SOD2, HSPA2 
   
Transcription 
factors 
Gene expression   
factors 
CREB1, SIRT1, STAT5A, 
PPARA, NFκB1   






APP, SPARC  
signaling Modulator DBI 
 
 
Table 3.1 Implicated and novel genes for mRNA gene expression in DD* 
 
systems including HSPA2 and PSMA4 (Vawter et al., 2006; Bousman et al., 2010). Finally, 
oxytocin (OXT) and the oxytocin receptor (OXTR) where included given their proposed 
role in appetite, anxiety, pleasure seeking, and stress (Slattery and Neumann, 2010). 
A novel feature of our study is that we also examined classes of genes that were 
not previously studied by the qPCR method in depression, though some have been 





This category consisted of genes involved in representing mitochondrial and metabolic 
functions such as the electron transport chain (ATP5E, COX5B, and NDUFS5) (Beech et 
al., 2010; Manji et al., 2012), and the growth factors Amyloid Precursor Protein (APP) 
which is implicated in Alzheimer’s disease as well as depression (Hock et al., 1998; 
Jakobsson et al., 2012; Pomara et al., 2012), and also neuregulin-1 (NRG-1) which is 
related to susceptibility to schizophrenia and potentially DD (Green et al., 2005; 
Petryshen et al., 2005). Further, our gene expression panel incorporated several ligand-
gated channels important in detecting metabolites potentially underlying symptoms of 
pain and fatigue: genes of the purinergic families (P2X ionotropic and P2Y metabotropic) 
that sense ATP metabolites, the transient vanilloid receptor (TRPV1, TRPV4) involved in 
the detection of heat, acid, pressure, and osmolarity, and the acid-sensing ion channels 
(ASIC1, ASIC3) important for sensing changes in protons. Changes in gene expression 
have been found to be associated with pain and fatigue in patients with Fibromyalgia 
(FM) and Chronic Fatigue Syndrome (CFS) (Light et al., 2009; Light et al., 2012a), who 
often have co-morbid depression. Several of the genes above have also been implicated 
in animal models of depression and anxiety. For example, animal studies have found 
that ASIC1a KO mice and WT mice treated with ASIC1a inhibitors display nondepressive 
and nonanxiolytic behavior (Coryell et al., 2009; Dwyer et al., 2009). Similarly, agonists 
and KOs of ASIC3, P2Y1, TRPV1, and P2X7 have been shown to modulate behavior in 
rodent tasks that simulate depressive symptoms (Kittner et al., 2003; Basso et al., 2009; 
Micale et al., 2009; Wu et al., 2010; Hayase, 2011; Manna and Umathe, 2012). Of these, 





P2X7 may predispose individuals to depressive disorders, though gene expression 
studies have not been conducted (Lucae et al., 2006).  
 Thus, the primary aim of our study was to determine if mRNA gene expression is 
dysregulated in both female and male medication-refractory patients for pathways 
previously implicated in depression, as well as novel pathways involved in depression 
symptoms. Results may identify new candidate mechanisms for depression-related 
research and potentially future targets for antidepressant drug development.  
 
Materials and Methods 
Subject 
 All subjects gave written consent, and protocols were reviewed and approved by 
the institutional review board. The Depression (DD) group included 42 individuals (23 
females) in an active state of moderate to severe depression that had unsatisfactory 
response to 3 or more different antidepressant medication regimens.  They included 25 
patients with a primary diagnosis of major depressive disorder (MDD) (13F/12M) aged 
21-69 years, and 17 patients with bipolar disorder (BPD) (10F/7M) aged 20-72 years (see 
Table 3.2).  
 Clinical assessment was carried out including the Hamilton Rating Scale for 
Depression (HRSD-24), administered by trained personnel and experienced psychiatrists, 
and the Quick Inventory of Depressive Symptomatology-Self Report Scale (QIDS-SR). The 
control group, which included 49 individuals, also completed the QIDS-SR to assess their 






    Control MDD   BPD DD(combined) 






43.7±2.2 43.9±2.6 41.4±3.7 42.9±2.2 
Gender(Male/Female) (19/19) (12/13)  (7/10) (19/23) 
HRSD 
   
36.4±2.2  32.1±2.3 34.8±5.4 
No medication 
 
36 1  0 1 
Antidepressants 0 22  10 32 
Anticonvulsants (N/S/C)b   (36/0/3) (7/3/15)  (4/1/12) (11/4/27) 
Antipsychotic   0 14  10 24 
 
aAntidep use has higher in MDD vs. BPD χ2=4.749 (p =0.03) and vs. CON (p <0.01)  
bAnticonvulsant (N = not on, S = stopped in anticipation of ECT, C = currently on) 
 
Table 3.2 Demographic summary for CON and DD 
 
information including history of depression and other mental disorders. The control 
group was further divided into two groups: 1) CON (n = 38) had no history of depression 
or current symptoms of depression (19 females, mean age 43.9 ± 2.1) and 2) CON-DD (n 
= 11) had a history of clinical depression and/or were currently taking an antidepressant 
(7 females, mean age 39.4 ± 3.7). Concurrent with behavioral assessment, blood 
samples were obtained from each participant. All participants were nonpregnant and 
between 20 and 76 years old. Patients and controls were matched for age and sex, with 
no significant differences between groups. Antidepressant use was significantly higher in 





p < 0.001) (since no CON subjects were on antidepressants). There were no differences 
in anticonvulsant use between MDD and BPD. 
 
mRNA extraction and analysis 
 All blood processing and analyses were performed by personnel blinded to the 
subjects’ group. Blood was collected in EDTA tubes and kept on ice, and within 15 
minutes after collection, the blood was centrifuged at 3200 rpm (1315 x g- Clay Adams 
Compact II Centrifuge) for 12 minutes, plasma was removed, and the white layer was 
carefully collected in RLT+β-ME (Qiagen, Valencia, CA), then quickly frozen using a 
methanol-dry ice slurry, and stored at -80ºC. RNA was extracted using RNeasy mini kits 
(Qiagen, Valencia, CA), and treated with RNase-free DNase-I (Qiagen, Valencia, CA). 
Immediately following extraction, RNA was converted to a cDNA library using the ABI 
High Capacity cDNA Archive Kit (Applied Biosystems/Life Technologies, Inc., Foster City, 
CA), followed by treatment with RNase-H (Epicentre Biotechnologies, Madison, WI). The 
cDNA samples were stored at -20o C until further use. RNA integrity was assessed with a 
Bioanalyzer, and consistently found to have RIN values (RNA integrity numbers) greater 
than 9.  The cycle counts for the control gene, TF2B, averaged 23.59 ± 1.04 (SD) for CON 
subjects and 22.82 ± 0.69 (SD) for DD patients. We selected TF2B as the preferred 
control gene and have verified that TF2B qPCR counts do not change in freshly 
harvested separated human leukocytes under a variety of conditions, when RNA is 





 The cDNA libraries were analyzed using the ABI quantitative, real-time PCR 
system on the ABI Prism 7900 Sequence Detection System (SDS) 2.4.1 (Applied 
Biosystems, Inc., Foster City, CA), using ABI TaqMan Master Mix (Applied Biosystems, 
Inc., Foster City, CA). Master Mix/primer plus primer/probe solutions and template 
solutions were separately loaded onto 96 well pre-plates. Then 384 well plates were 
robotically loaded and mixed from the 96 well plates. Each targeted gene was examined 
in duplicate, with TF2B standards being run in quadruplicate. Additional control samples 
containing no template were also run. Primer probes for the 46 candidate genes were 
obtained from TaqMan Gene Expression Assays (Applied Biosystems, Inc., Foster City, 
CA) and are listed in Table 3.3. qPCR data were processed using the SDS program with 
count values for genes computed in the curve log-linear using a standard 0.2 threshold. 
Gene expression amounts were determined using the 2-ΔT method, where ΔT is the 
count difference of the candidate gene from TF2B. 
 
Statistics 
 All statistical tests were made using STATA ver. 12 statistical software. Unpaired 
Student’s t-tests for all genes were first performed to identify any differences in gene 
expression between MDD and BPD. It turned out that only a single gene, TNFα was 
significant (p = 0.02) in a two tailed test while all others were not significant (p> 0.05; 





Gene Symbol ABI numbers  Gene Symbol ABI numbers 
TF2B Hs00155321_m1  NR3C2 Hs01031809_m1 
ADR2A Hs00265081_s1  NRG1 Hs00247620_m1 
ADR2C Hs03044628_s1  OXT Hs00792417_g1 
ADRB1 Hs02330048_s1  OXTR Hs00168573_m1 
ADRB2 Hs00240532_s1  P2X1 Hs00175686_m1 
APP Hs01552283_m1  P2X4 Hs00175706_m1 
ASIC1 Hs00241630_m1  P2X7 Hs00175721_m1 
ASIC3 Hs00245097_m1  P2Y1 Hs00704965_s1 
ATP5E Hs00855401_g1  P2Y2 Hs04176264_s1 
COMT Hs00241349_m1  PPARA Hs00947537_m1 
COX5B Hs00976765_g1  PSMA4 Hs01002583_m1 
CREB1 Hs00231713_m1  SIRT1 Hs01009006_m1 
CXCR4 Hs00607978_s1  SOD2 Hs00167309_m1 
DBI Hs00220950_m1  SPARC Hs00234160_m1 
DRD4 Hs00609526_m1  STAT5A Hs00234181_m1 
GZMA Hs00989184_m1  SULT1A1 Hs00738644_m1 
HCN2 Hs00606903_m1  TLR4 Hs00152937_m1 
HSPA2 Hs00745797_s1  TNFα Hs00174128_m1 
HTR1D Hs00704742_s1  TNFβ Hs00236874_m1 
IL-10 Hs00174086_m1  TRPV1 Hs00218912_m1 
IL-6 Hs00174131_m1  TRPV4 Hs01099348_m1 
NDUFS5 Hs02578754_g1  VEGFA Hs99999070_m1 
NFKB1 Hs00765730_m1  VIPR2 Hs00173643_m1 
NR3C1 Hs01005217_m1      
 









group for subsequent analyses vs. controls. When gender subgroups were next 
examined, we found a significant difference in TF2B reference gene in males vs. females 
in the CON group (23.21 ± .19 vs. 24.05 ± .24 for females vs. males, p < 0.001) but not in 
the DD group (22.81 ± .16 vs. 22.85 ± .14 for females vs. males, p = 0.86). This further 
supported our plan to examine males and females separately. 
 Our primary statistical approach compared DD vs. CON males and DD vs. CON 
females for each mRNA under study using General Linear Models (GLM) analysis of 
covariance, with age and reference gene TF2B level retained as covariates in the final 
model if they were significant at p < 0.05 or if they altered the coefficient of the main 
variable by more than 10 %. This procedure controlled for the difference in TF2B counts 
we observed in females vs. males subjects. For post hoc analyses examining effects of 
medications on mRNA level, males and females DD patients were examined together 
because of insufficient sample sizes for separate analysis, and gender was included as a 
covariate. When our analyses yielded a significant main effect of group, subsequent 
mean comparisons were made using Student’s t-tests with unequal variance. Genes 
were further tested for Pearson correlations with other genes and depression severity. 
Level of significance was set at p < 0.05 for two-tailed comparisons.  
 
Results 
Differentially expressed genes in DD compared to CON 
Our 46 candidate gene panel included genes from diverse functional classes. 





significantly increased in DD relative to controls [APP (p = 0.004), IL-10 (p = 0.035), IL-6 
(p = 0.044), OXTR (p = 0.023), P2X7 (p = 0.048), P2Y1 (p = 0.002), TRPV1 (p = 0.023)] and 
NRG1 showed a trend towards increase (p =0.069) (see Table 3.4). Of these, only APP 
was effected by specific diagnosis, showing elevated levels in female BPD (7.63x10-1) but 
not female MDD (5.98 x10-1) patients vs. female CON (5.65 x10-1, p = 0.003 and p = 0.537 
respectively). 
In males, none of the above genes were statistically different.  Instead we 
observed that three other genes were significantly different between DD and controls. 
We found increased expression in the DD males for ASIC3 (p =0.04), and decreased 
expression for ADRB2 (p =0.049) and DBI (p =0.003). Box and whisker plots displaying 
significant genes in males and females are shown in Figures 3.1-3.3. 
 
Medication effects on gene expression 
 Our previous report suggested that medications can affect gene 
expression, specifically it can mask possible differences between depressed and 
nondepressed populations (Iacob et al., 2013). We therefore examined the within-group 
effects of different classes of medication combining males and females. Because we 
observed gender differences for gene expression, we included gender, age, and TF2B as 
covariates in the regression models where appropriate. 
Patients on antipsychotic medications, (24 of the 42 patients) displayed higher 
CREB1 (7.19x10-1 for patients taking antipsychotics vs. 6.36x10-1, p = 0.03 for patients 
































































































































       CON    DD           CON    DD            CON    DD          CON    DD 
Figure 3.1 Box and whisker plots displaying mRNA gene expression Relative Quantity 
to TF2B (RQ). White boxes represent CON, and grey boxes represent DD.  Depressed 
females display increased levels of APP, IL-10, IL-6 and NRG-1. *p <0.05 in Student’s 





























































































       CON    DD           CON    DD            CON    DD          CON    DD 
Figure 3.2 Box and whisker plots displaying mRNA gene expression Relative Quantity 
to TF2B (RQ). White boxes represent CON, and grey boxes represent DD.  Depressed 
















































































       CON    DD           CON    DD            CON    DD          CON    DD 
Figure 3.3 Box and whisker plots displaying mRNA gene expression Relative Quantity 
to TF2B (RQ). White boxes represent CON, and grey boxes represent DD.  Depressed 
males display decreased levels of ADBR2 and DBI, and increased levels of ASIC3. *p 





























          CON      DD                           DD 
Figure 3.4 Box and whisker plots displaying mRNA gene expression Relative 
Quantity to TF2B (RQ). White boxes represent CON, and grey boxes represent DD.  
DD not taking antidepressants display significantly higher NRG-1 levels than both 
medication-naïve CON and medicated DD. There was no CON subject who was 
taking antidepressants. *p <0.05 in Student’s t-test. 
 
 Patients taking any class of antidepressants (32 of 42) displayed decreased levels 
of NRG1 (9.24x10-4 vs. 1.67x10-3, p < 0.01). Since DD females had marginally higher 
levels of NRG1 compared to CON, this suggests that medications could have a masking 
or normalizing effect on this gene. In fact, our Generalized Linear Model (GLM) using 
antidepressant use as a covariate revealed a highly significant difference between CON 







However, since only 4 females and 6 males in the DD group were not currently on 
antidepressants, subsequent research with larger samples will need to re-examine this 
post hoc observed possibility. Conversely, patients on antidepressants showed 
significantly lower P2Y2 expression compared to those not on antidepressants (9.48x10-
2 vs. 1.21x10-1, p = 0.03). Even with inclusion of antidepressant medication as a 
covariate, however, P2Y2 differences remained nonsignificant when comparing DD 
females or males vs. CON (p =0.870, p = 0.737 respectively).  
 Finally, use of anticonvulsants was examined. There were 11 patients not on 
anticonvulsants, 4 who stopped in anticipation of ECT treatment, and the remaining 27 
were on some type of anticonvulsant. Within group ANOVA analysis for these three  
groups and subsequent post hoc unpaired t-tests showed that patients taking  
 anticonvulsants displayed higher ASIC3 (7.69x10-3 vs. 4.9x10-3, p <0.001), higher NR3C2 
(5.92 x10-2 vs. 4.44x10-2, p < 0.005), higher SULT1A1 (7.61x10-4 vs. 5.55x10-4, p = 0.02), 
and higher TRPV1 (1.43 x 10-2 vs. 1.21x10-2, p = 0.04) compared to subjects that were 
not on any anticonvulsants. Figure 3.5 shows the effects of anticonvulsants on ASIC3 
and TRPV1.Importantly, addition of anticonvulsant use as a covariate resulted in loss of 
a group effect for TRPV1 (p = 0.286) between DD females vs. CON, and loss of group 
effect for ASIC3 (p = 0.717) between DD males vs.CON, suggesting that medication 











































no anticonv       on anticonv
con dep con dep
no anticonv       on anticonv
con dep con dep
 
Figure 3.5 Box and whisker plots displaying mRNA gene expression Relative Quantity 
to TF2B (RQ). White boxes represent CON, and grey boxes represent DD.  DD 
patients on anticonvulsants displayed increased ASIC3 and TRPV1. *p <0.05 in 
Student’s t-test  
  
Gene expression relationship to depression severity 
 To ascertain if gene expression was related to depression severity, we examined 
correlations between mRNA levels and HRSD score in the DD patients. Females 
displayed significant negative correlations for ADRB2 (-0.42, p = 0.047), NR3C1 (-0.43, p  
= 0.043), and SULT1A1 (-0.41, p = 0.05). For males, there were positive correlations with 
severity for CXCR4 (0.55, p = 0.018) and HCN2 (-0.51, p = 0.03). None of these genes 








The principal finding of this study is that women with medication-refractory 
depression display circulating immune gene mRNA expression differences compared to 
healthy, nondepressed controls. These differences include increased expression of APP, 
IL-10, IL-6, NRG1, OXTR, P2Y1, and TRPV1. These genes were not differentially expressed 
in depressed males, who instead displayed increases in ASIC3 and decreases in ADBR2 
and DBI gene expression. Furthermore, within-group analysis suggests that most of 
these differences were not due to concurrent anticonvulsant, antidepressant, or 
antipsychotic use, with the exception of TRPV1 in females and ASIC3 in males, where 
anticonvulsant medications appear to contribute to the observed effects. 
Antidepressant use masked differences in NRG1. The potential biological significance for 
the genes displaying differential expression is discussed below. 
 
Immune cytokine genes IL-10 and IL-6 are upregulated in depression 
Depression has long been associated with alterations in immune function and 
the stress response. Interestingly, although many studies report an increased immune 
activation with increased inflammatory markers and T-cell activation, there are also 
reports of immune suppression, such as decreased lymphocyte proliferation in response 
to mitogens and decreased natural killer cell cytotoxicity, suggestive of overall 
dysregulation of both processes (Miller et al., 2009; Blume et al., 2011; Messay et al., 
2012). Since white blood cells mediate the immune response, helping with cross-talk 





immune genes and indeed found upregulation in IL-6 and IL-10 in females with 
medication-refractory depression.  
Elevated blood IL-6 protein is a consistent finding in depression and some studies 
suggest that IL-6, and concomitant pro-inflammatory mechanisms, are specifically 
associated with treatment-resistant depression (Maes et al., 1997; Lanquillon et al., 
2000; Simon et al., 2008; Howren et al., 2009; Dowlati et al., 2010). Few studies have 
examined IL-6 mRNA levels, with most of the ones that did showing increased IL-6 
expression in depressed subjects (Padmos et al., 2008; Cattaneo et al., 2013; Iacob et al., 
2013) though some studies report no difference (Belzeaux et al., 2010). Importantly, 
some studies suggest that the expression of IL-6 and several other genes is differentially 
reduced in patients who respond to treatment compared with those that do not 
(Yoshimura et al., 2009; Cattaneo et al., 2013).  
IL-10 plays a primarily anti-inflammatory role by inhibiting production of pro-
inflammatory cytokines and NFκB1. Previous studies have found increased serum levels 
of IL-10 in patients with depression, in both treated and medication naïve subjects, 
although other studies found no differences (Hernandez et al., 2008; Simon et al., 2008; 
Dowlati et al., 2010; Cattaneo et al., 2013). IL-10 mRNA has also been found to be 
elevated in patients with depression (Belzeaux et al., 2010; Iacob et al., 2013). 
Importantly, both protein and mRNA levels decreased following successful treatments 
(Sullivan et al., 2006; Hernandez et al., 2008; Iacob et al., 2013).   
Our results together with those in the literature suggest that IL-6 and IL-10 are 





Increases in mRNA for IL-6 together with IL-10 correspond to a common underlying 
mechanism in depression and we believe that IL-10 and IL-6 will continue to be 
promising biomarkers for depression. Further examination of changes in gene 
expression in these and other cytokines following symptom improvement may help to 
determine if mRNA levels of cytokines could serve as a predictor of treatment efficacy.  
 
Amyloid Precursor Protein is upregulated in BPD females 
We observed that female patients with depression displayed elevated levels of 
Amyloid Precursor Protein (APP) mRNA compared to healthy nondepressed controls. 
Subsequent analysis with diagnosis as a covariate revealed that females with BPD, but 
not MDD, had higher levels of APP compared with female CON. This is of interest given 
that BPD and MDD patients were not distinguished by any other gene in our profile 
when studied during an episode of depression vs. CON.   
In addition to their well-known potentially important roles in Alzheimer’s disease 
(Rapp et al., 2006; Butters et al., 2008; Hardy, 2009; Ono and Saji, 2012), amyloid 
peptides have also been examined in depression. Given that depression is a common co-
morbidity as well as a risk factor for Alzheimer’s disease (Green et al., 2003), APP may 
have functional significance in MDD and other depressive disorders.  First, Hock et al. 
observed that there were no differences in APP or amyloid Aβ peptides in the cerebral 
spinal fluid (CSF) of elderly Alzheimer’s patients or age-matched depressed controls 
(Hock et al., 1998). Furthermore, studies in the elderly have found CSF Aβ40 and Aβ42 





(Pomara et al., 2012), though both increased and decreased levels of Aβ42 have been 
found in human plasma (Sun et al., 2007; Moon et al., 2011). Perhaps most important is 
that Baba et al. observed that decreased serum Aβ42 is not restricted to the elderly 
depressed population: similar decreases were observed in young and middle-aged 
depression groups (Baba et al., 2012). Alterations in CSF APP peptides have also been 
observed in young patients with BPD, including decreased levels of sAPP-α and sAPP-β 
in Bipolar type I and changes in Aβ peptides in Bipolar type II (Jacobsen and Mork, 
2004). Our results of increased APP gene expression may be due to compensation for 
low levels of peptides, or to nonfunctional peptides. Given the complex post 
transcriptional processing of APP, future studies could potentially combine imaging and 
blood analysis to determine the relationship between central amyloid levels and 
peripheral gene expression in depression patients. 
 
Increased expression of NRG1 in refractory depression 
We found a trend towards increased mRNA expression of NRG1 in DD females 
vs. CON, a difference that became robustly significant after inclusion of antidepressant 
use as a covariate. NRG1 functions through EGF-like domains to stimulate ErbB tyrosine 
kinases, leading to downstream events important for neural development, including 
growth and differentiation of neural precursor cells, axon guidance, and synaptic 
transmission (Falls, 2003). It is postulated that developmental dysruptions in migration 
and wiring potentially related to NRG1 and glutamatergic activity can lead to symptoms 





disorders (Mei and Xiong, 2008). NRG1 is a good example of the complex gap between 
mRNA and protein, since NRG1 can give rise to over 30 isoforms and it is unclear how 
changes in expression impact function. In rodents, subcutaneous, functional NRG1 has 
been shown to induce adult neurogenesis and antidepressant-like effects (Mahar et al., 
2011). Genetic studies suggest that the NRG1 gene is related to susceptibility to 
schizophrenia (Mei and Xiong, 2008) and more recently to BPD (Green et al., 2005; 
Thomson et al., 2007), though Schosser et al. were not able to find a relationship to 
MDD (Schosser et al., 2010). Changes in mRNA for NRG1 have been observed in neural 
tissue, with both increases and decreases in NRG1 depending on the isoform, in 
schizophrenia and unipolar depression (Hashimoto et al., 2004; Bertram et al., 2007). In 
blood, NRG1 gene expression has been shown to be elevated in leukocytes of patients 
with schizophrenia (Petryshen et al., 2005). Although gene expression of NRG1 has 
previously been shown to be elevated in a study of 11 patients with depression 
(Belzeaux et al., 2010), we are the first to show upregulation of NRG1 in medication-
refractory patients. Future analysis examining whether symptoms are related to NRG1 
functional polymorphisms and expression could help determine if NRG1 could serve as a 
biomarker for at least some forms of depression.  
 
Increased oxytocin receptor in medication-refractory females 
 Oxytocin, a neuropeptide synthesized and released by the hypothalamus, has 
been implicated in many biological functions, including social bonding, anxiety, 





depression (Slattery and Neumann, 2010). The oxytocin receptor is a G-protein coupled 
receptor (GPCR) that signals through phospholipase C to mobilize internal calcium. 
Though oxytocin has been shown to be anxiolytic, antidepressant, and anti-nociceptive, 
plasma and CSF levels in depressed humans are inconclusive, with reports of both 
increased and decreased levels compared to controls (Slattery and Neumann, 2010). 
However, Cyranowski et al. suggest that absolute levels of oxytocin may not be as 
important as is its proper regulation. For example, they found that depressed females 
displayed greater oxytocin variability compared to controls over the course of one hour 
in two separate behavioral tasks, with higher levels associated with clinical and self-
report depressive symptoms (Cyranowski et al., 2008). This increased variability in MDD 
patients is also supported by a study combining both males and females (van Londen et 
al., 1997). Our findings of increased oxytocin receptor mRNA may reflect receptor 
upregulation in response to low or poorly functioning oxytocic activity, whereas 
overstimulation would lead to receptor desensitization, internalization, and decreased 
mRNA (Gimpl and Fahrenholz, 2001). Interestingly, we did not find any other studies 
that have examined oxytocin receptor blood gene expression in patients with depressive 
disorders.  
 Several studies examining postmortem tissue comparing depressed patients 
following suicide vs. nondepressed controls found increased oxytocin immunoreactive 
cells in the paraventricular nucleus of the hypothalamus (Purba et al., 1996), trend 
towards increased hypothalamic oxytocin mRNA (Meynen et al., 2007), and trend 





review, Slattery et al. suggest that oxytocin activity is increased in the brain in order to 
offset decreased release in the periphery (Slattery and Neumann, 2010). However, since 
acute events such as suicide may change gene expression, it will be important for future 
studies to examine changes in oxytocin mRNAs before and following treatment. 
 
Increased expression of receptors of the ASIC, TRPV, and P2 types and 
potential implications in pain and fatigue 
 Our gene expression panel also consisted of several ligand-gated channel 
families important in detecting ATP and other metabolites associated with aerobic and 
anaerobic metabolism. Of the nine receptors that we examined, four displayed 
differences during a depressive episode: P2X7, P2Y1, and TRPV1 were upregulated in 
females and ASIC3 was upregulated in males. However, our subsequent analyses 
showed that anticonvulsant use was associated with a significant increase in both TRPV1 
and ASIC3, and when reanalyzed after controlling for this medication, only P2X7 and 
P2Y1 in females remained statistically significant (see medication effects below).  
 Our research group previously found that following a moderate exercise task, 
when their fatigue and pain symptoms worsen, patients with CFS (but not controls) 
show increased expression of ASIC3, P2X4, P2X5 and TRPV1 receptors (Light et al., 2009; 
Light et al., 2012a). These studies suggest a possible mechanism by which higher 
receptor expression leads to increased sensitivity to ATP, lactate and other metabolites, 
and thus the symptoms of pain and fatigue, which are also common in depression. 





were specifically associated with comorbid FMS pain in our CFS patients) are not directly 
altered by anticonvulsant use, but are instead biomarkers of those patients who will 
most benefit from anticonvulsant treatment; it is notable that anticonvulsants are FDA-
approved treatments for FMS and neuropathic pain (Sullivan and Robinson, 2006).  
 Our clinical findings in regard to P2Y1, P2X7 and TRPV1 mRNAs are the first such 
observations in depressed humans, but are consistent with a number of preclinical 
studies. P2Y1 receptor agonists have been shown to display anxiolytic properties in 
rodents in the EPM, while P2X7 KO mice displayed normal behavior in the elevated plus 
maze (EPM), but nondepressed-like behavior in other tests (Kittner et al., 2003; Basso et 
al., 2009). In humans, it has been suggested that a polymorphisms in P2X7 may 
predispose individuals to MDD depressive disorders, though these findings have been 
disputed by some (Lucae et al., 2006; Green et al., 2009; Skaper et al., 2010). TRPV1 
channels have also been implicated in animal models of depression and anxiety, with 
intraperitoneal injections of TRPV1 antagonists having anxiolytic effects while TRPV1 
agonists were anxiogenic (Micale et al., 2009). In the brain, intracranial injections of 
TRPV1 agonists or antagonists were found to have antidepressant effects, perhaps by 
decreasing NMDA-mediated activity (Manna and Umathe, 2012). 
 
Adrenergic receptor β2 and GABA modulator DBI 
 Two additional genes [adrenergic receptor β 2 (ADRB2) and diazepam binding 
inhibitor (DBI)] differed between DD and CON groups, but for males only. There was a 





catecholamine signaling that is important for smooth muscle relaxation in the 
vasculature and lungs, and for increasing heart rate when more cardiac output is 
necessary. The ADRβ2 agonist salbutamol has been found to have beneficial effects in a 
clinical trial with depressed patients (Belmaker, 1981). Furthermore, Mausbach et al. 
found that peripheral cell β2-receptors desensitized in individuals taking care of spouses 
with Alzheimer’s Disease (Mausbach et al., 2008). Finally, numerous polymorphisms 
have been identified that may result in altered expression of β2-adrenergic receptors 
including in asthma, various heart conditions, and obesity (for review see (Small et al., 
2003)). In fact, previous research has found that adrenergic function including α2A-, β1-, 
and β2-, receptors are perturbed in animal models of stress and depression with 
differential changes under acute and chronic stress (Goddard et al., 2010). Given the 
heterogeneity of depression, it is not unreasonable to assume that multiple subtypes of 
adrenergic receptors can be dysregulated. In the Chapter 2 study examining stress and 
immune-related genes, we found gene expression trait-dependent differences in ADR2A 
and ADRB1 but not ADRB2, though our sample size consisted primarily of unipolar 
depression patients, with males and females grouped together (Iacob et al., 2013). 
Because of their antagonistic functions, the ratio of β and α receptor expression may be 
important, as suggested by a postmortem study comparing suicide patients vs. controls, 
and thus future studies should continue to include adrenergic receptors as promising 
biomarkers for depression (Sastre et al., 2001). 
 The second gene decreased in males was the GABAA negative modulator DBI, a 





depression, including observation of elevated CSF protein levels in depressed subjects 
(Barbaccia et al., 1986). We had previously observed increased DBI levels in refractory 
depression that remain elevated despite symptom improvement following ECT (Iacob et 
al., 2013). Because GABAA receptors act to inhibit neurons that produce corticotropin 
releasing hormone (which normally leads to increased cortisol), DBI dysregulation may 
contribute to HPA hyperactivity, observed in 50% of depressed patients. Furthermore, 
since DBI can interfere with the efficacy of commonly prescribed benzodiazepines, DBI 
dysregulation could contribute to nonresponse to medication in depressed patients with 
comorbid anxiety (Taupin et al., 1991). Future studies should evaluate the relationship 
between peripheral expression of DBI, anxiety, and treatment response.   
 
Effects of medications and depression severity 
In line with previous studies, we found that use of specific classes of medications 
was associated with significantly altered gene expression, masking or potentiating 
differences between patients and controls (Choi et al., 2009; Belzeaux et al., 2010). In 
the case of NRG1, use of SSRI, SNRI and NRI antidepressants may have masked 
differences between DD and CON for both males and females by decreasing gene 
expression. Dysfunctional NRG1 has been proposed to contribute to neurological 
disorders, including schizophrenia, by potentiating GABA and thus impairing 
glutamatergic signaling (Falls, 2003; Mei and Xiong, 2008). It is possible that modulation 
of monoamine and glutamate signaling with antidepressants leads to homeostatic 





Conversely, as discussed previously, anticonvulsant use may have potentiated 
differences in expression of some genes, specifically ASIC3 in males and TRPV1 in 
females. Though studies have examined the effects of anticonvulsants on gene 
expression, few have examined anticonvulsants in regard to depression (Tang et al., 
2004; Hassel et al., 2010). Given that it is not practical or ethical to stop medications if 
they demonstrate at least partial therapeutic benefits, these results suggest that 
medications, including anticonvulsants, must be considered as potential confounders 
when interpreting gene expression results. Additional research examining expression of 
these genes before and after such antidepressant and anticonvulsant therapy is initiated 
would be valuable. 
In our study, we did not find that depression severity was related to any of the 
genes that were differentially expressed in the primary analysis. However, female DD 
displayed negative correlations for depression severity and ADBR2, NR3C1, and SULT1A1 
mRNA quantities. For DD males, CXCR4 had a positive correlation to depression severity 
while HCN2 had a negative correlation. Studies examining changes in gene expression 
following symptom improvement may be able to elucidate if these relationships are of 
any consequence.  
 
Summary 
The onus is on physicians to acquire better biological readouts for as yet poorly 
understood diseases, including depressive disorders. In this study, we examined patients 





underlying their treatment resistance. Using this method, we made observations 
supporting dysregulation in genes previously implicated in depression, such as immune 
cytokines IL-10 and IL-6, but also reported on differences for genes involved in other 
disorders including APP (Alzheimer’s disease), NRG1 (schizophrenia) and P2X7 and P2Y1 
(pain and fatigue). This is not surprising given the prevalence of depression as a 
common co-morbidity, and highlights the importance of research into shared biological 
mechanisms underlying disease. It is important to note, however, that depression 
remains enigmatic and difficult to treat, partially because of the diversity of disease 
onset, variability of symptom presentation, and demographic heterogeneity. Each 
different sample group may contribute a unique set of gene dysregulation and 
therefore, it may likely take numerous studies to uncover a gene expression signature 
for DD. By amassing a panel of differentially expressed genes, researchers could 
continue to identify novel biological mechanisms contributing to depression and 
potentially pave the way to new drug targets and personalized medicine. Future studies 
should combine examination of treatment-resistant and treatment-responsive patients 
in prospective studies to examine differences before and after medication as well as 
following moderate exercise tasks found to differentiate patients with CFS and FM from 
controls (Light et al., 2009; Light et al., 2012a).  
 
Study limitation 
One noteworthy limitation in this study is the observation of higher amounts of 





of total mRNA, it would indicate that processed blood from DD subjects had higher 
proportion of white blood cells. It has been suggested that patients with depression 
exhibit both immune suppression and activation including more reactive platelets 
(Musselman et al., 1996), higher monocyte counts and activation (Rothermundt et al., 
2001; Beumer et al., 2012), but decreased natural killer cell cytotoxicity (Pike and Irwin, 
2006; Blume et al., 2011). Changes in cell counts may also be related to immune 
differences observed. For example, Lanquillon et al. suggest that there may be a 
relationship between monocytes and IL-6 levels in treatment nonresponders (Lanquillon 
et al., 2000). It is important for future studies to specifically regard cell-type specific 
populations in changes of gene expression. Current experiments are under way to 
better understand the relationship between total TF2B, RNA quantity, cell types, and 




































Biological Implications of Gene Expression and Future Directions 
Overview 
The aim of this dissertation was to explore candidate gene expression 
dysregulation in depressive disorders (DD) using real-time quantitative PCR (qPCR). This 
was based on the hypothesis that DD display both central and peripheral dysfunction 
and that examination of circulating peripheral blood leukocytes can reflect brain 
neurophysiology (Gladkevich et al., 2004; Sullivan et al., 2006; Iga et al., 2008). 
Furthermore, because DD are a heterogeneous group of disorders with diverse 
symptomatology, we chose to examine medication-refractory patients since they would 
likely display the most severe symptoms and novel biological mechanisms. In Chapter 2, 
as part of an add-on study examining a novel treatment using anesthesia, we found that 
gene expression representing immune function was dysregulated prior to treatment in 
19 patients with medication-refractory depression who nonetheless responded to ECT 
or anesthesia. Furthermore, gene expression displayed primarily two patterns following 
treatment: 1) trait-dependent expression with few changes suggesting continued 
dysregulation 2) acute changes 24 hours after ECT that recovered to original levels at 
one month Follow-up. However, diminishing Follow-up samples only permits 
conservative conclusions. In Chapter 3 we describe an exploratory study with a larger 
sample size of 42 patients and 38 controls and with an expanded gene expression panel 
of 46 genes. Because of preliminary evidence of potential gender effects, we examined 
gene expression separately by gender. Encouragingly, we found dysregulation in IL-10 





previously implicated in pain and fatigue, Alzheimer’s disease, and neuronal 
development. It is likely that each sample set will have a unique gene expression profile. 
It will be important in future studies to continue exploring the possible implications of 
our findings in both clinical and animal models. qPCR results showing possible 
association of gene expression dysregulation with depression may lead towards a better 
understanding of biological pathways underlying disease. 
 
Patients with refractory depression display state and 
trait-dependent gene dysregulation 
 In Chapter 2 we describe gene expression for immune and stress-related genes 
in patients before and after treatment with ECT or the anesthetic isoflurane (behavioral 
consequences are described in the Appendix). This study was unique in that we 
examined a subgroup of medication-refractory patients who all received similar care 
and only one of two treatments. We found that depressed subjects displayed 
dysregulation in adrenergic receptors ADR2A and ADRB1, the GABAA modulator DBI, and 
the serotonin receptor HTR1D, all of which remained dysregulated even following 
treatment and symptom improvement. All of these genes have been minimally 
evaluated in previous studies using qPCR in blood leukocytes of depressed patients 
though adrenergic receptors (Goddard et al., 2010), HTR1D (Arranz et al., 1994; Lowther 
et al., 1997) and DBI (Barbaccia et al., 1986) have all been implicated in depression and 
anxiety. We also detected increases in immune cytokines IL-6 and IL-10, and the 





we are unable to draw conclusions about changes in these genes following symptom 
improvement although IL-10 and NFκB1 show normalizing trends to control levels. Both 
protein and mRNA for IL-6 and IL-10 cytokines have previously been shown to be 
elevated in depression (Tsao et al., 2006; Belzeaux et al., 2010; Dowlati et al., 2010) and 
thus our studies support their use as biomarkers for depression. NFκB1 is an important 
transcription factor that mediates many target genes involved in pro-inflammatory and 
immune response (Miller et al., 2009); for instance. A study by Miller et al. describes 
increased number of transcripts having NFκB1 response elements in subjects under 
chronic stress thus further supporting the hypothesis of chronic immune dysregulation 
(Miller et al., 2008). Our study is the first to report on changes in mRNA levels of NFkB1 
in peripheral cells. Additionally, the dopamine receptor DRD4 and glucocorticoid 
receptor NR3C1, which were normal at Pretreatment, displayed acute decreases 
immediately Posttreatment, but returned to Pretreatment levels at Follow-up. This is 
consistent with numerous studies that suggest ECT has acute, but not long-lasting 
effects (Fluitman et al., 2011). Finally, we only found one gene that displayed lasting 
changes following treatment, namely SULT1A1 which codes for an enzyme responsible 
for aiding in hormone, NT, and drug metabolism (Coughtrie, 2002). SULT1A1 as not 
dysregulated at Pretreatment but decreased significantly at Posttreatment and Follow-
up. This is an attractive target for future studies, since it may play a role in increased 
medication-response seen following ECT. Therefore, in this small pilot study we 
identified dysregulation in mRNA gene expression in receptors and peptides previously 





following treatment.  
 
Novel dysregulation in patients with medication-refractory depression 
 In the study reported in Chapter 3 we recruited a much larger set of patients and 
age/gender-matched controls and examined a diverse panel of genes including 
expansion of immune markers, metabolite receptors implicated in pain and fatigue, 
genes involved in energy metabolism, and genes involved in neuronal developmental 
and plasticity previously implicated in such disorders as Alzheimer’s disease and 
schizophrenia. The aim of this study was to explore possible novel biological 
contributors to depression and relate them to separate concurrent work examining 
chronic fatigue syndrome, fibromyalgia, and prostate cancer. Given the higher 
frequency of depression in females (Kessler et al., 2005), we opted to examine gene 
expression separately by gender. Out of a panel of 46 genes, encouragingly, we 
confirmed elevated levels for immune cytokines IL-6 and IL-10 (in depressed females). 
These results continue to suggest immune dysregulation in depression and the need for 
further research into potential adjunctive pharmacotherapy, including the proposed use 
of anti-inflammatory medications (Miller et al., 2009; Raison et al., 2012). Of the 
adrenergic receptors, we found that depressed males had decreased ADBR2 compared 
to controls. Previous research has found that chronic stress can lead to desensitized 
receptor and the β-2 receptor agonist salbutamol was shown to have therapeutic 
benefits in a clinical trial for depression (Belmaker, 1981; Mausbach et al., 2008). In 





provide further evidence of dysregulation in norepinephrine and adrenergic function 
and merit further investigation as a means to monitor therapeutic response to 
conventional norepinephrine reuptake inhibitors (NRIs) or use of selective adrenergic 
agonists. Finally, males displayed decreased levels of the Diazepam Binding Inhibitor 
(DBI), a peptide that may have a role in indirectly activating HPA-axis and cortisol 
release by interfering with GABAA mediated inhibitor of CRF-releasing cells (Taupin et 
al., 1991). Our pilot study found that DBI expression was increased in patients with 
depression. Because of DBI’s potential role in anxiety, co-morbid anxiety in different 
patient populations may constitute distinct gene expression signatures. Future clinical 
and animal studies should examine the effect of DBI activity, benzodiazepines, and 
treatment response.    
 Important to this study was inclusion of numerous genes that were not 
examined in the Chapter 2 study. Thus, we included here several receptors important 
for the detection of ATP and other metabolites associated with aerobic and anaerobic 
metabolism. Depressed females displayed increased expression for purinergic receptor 
P2X7, P2Y1, and the transient vanilloid receptor TRPV-1, all of which have roles in 
animal models of depression and anxiety (Kittner et al., 2003; Basso et al., 2009; Micale 
et al., 2009; Manna and Umathe, 2012). Furthermore, these receptors show marked 
increases in patients with CFS, but not in controls, following a moderate exercise, which 
correlated to pain and fatigue scores (Light et al., 2009; Light et al., 2012b). This 
suggests that acute mild stress leads to gene expression dysregulation and may underlie 





by chronic stress may have hyperactive sensory activity that would benefit from 
medications. Future studies will examine patients with depression on this task, with the 
hope that the results will allow separation of this disorder from commonly 
misdiagnosed co-morbidities.  
 The amyloid precursor protein (APP), which codes for a matrix cell surface 
receptor and soluble peptides, has numerous roles in neuronal and synaptic 
development (Zheng and Koo, 2006). Unfortunately, dysfunction in peptide transport 
and clearance can lead to synaptic plaques, which are one of the hallmarks of 
Alzheimer’s disease. Interestingly, while central levels are high, peripheral amounts of β-
amyloid peptides are low in both Alzheimer’s disease and depression (Fagan et al., 2006; 
Rapp et al., 2006; Baba et al., 2012). We are the first to show upregulated APP mRNA in 
patients with depression (in our sample it was restricted to the patients with BPD) which 
might be due to an effort to compensate for decreased or nonfunctional peptides. 
Future studies should evaluate the relationship, if any, between peripheral APP mRNA 
expression and central amyloid using neuroimaging in DD. Another protein involved in 
neuronal development is the growth factor neuregulin (NRG)-1, genetic dysfunction of 
which has been suggested to cause neuronal migration and disrupted glutamatergic 
activity that may underlie symptoms of schizophrenia and depression (Green et al., 
2005; Thomson et al., 2007; Mei and Xiong, 2008). We found upregulated NRG-1 in 
patients with depression specifically for those who were not currently taking 
antidepressants. If these results can be replicated, NRG-1 expression could be used to 





antidepressants. Animal studies should further investigate the role of NRG-1 in 
depressive symptoms and anxiety.  
 
Technical limitations 
 Though qPCR allows for quantification of small amounts of mRNA transcripts, it 
does have several technical limitations. First, sample preparation and separation 
methods can all impact gene expression, including evaluation of whole blood vs. 
individual cell types or poor protection from endogenous RNAses (Feezor et al., 2004; 
Asare et al., 2008). Additionally, the choice of internal reference genes for total mRNA 
normalization are critical (Bustin, 2005). Our research group has historically used TF2B, 
since we found that it remains stable before and following moderate exercise across 
multiple population groups. TF2B is a ubiquitous transcription factor necessary for 
transcription initiation by RNA polymerase II and has expression levels in the 
appropriate range compared to many candidate genes. Conversely, other commonly 
used reference genes like actin, GAPDH, and RNA 18S are either orders of magnitude 
more abundant, or have been shown to have variable expression. That being said, we 
found that control males in both Study 1 and Study 2 displayed lower TF2B mRNA 
compared to depressed males whereas these differences were absent for females. If 
TF2B is a proper surrogate for total mRNA, this suggests that males with depression may 
have higher mRNA in the buffy coat layer, which is composed of white blood cells 
(WBCs) and some platelets. Though WBCs contribute the majority of mRNA, platelets 





WBCs) and can synthesize proteins despite lacking a nucleus (Kabanova et al., 2009; 
Flaumenhaft, 2011). Furthermore, platelets are known to express P2 receptors including 
P2X1 and P2Y1 (Clifford et al., 1998). Therefore, differences in proportion of platelets 
and WBCs or sample separation could lead to variation in gene expression. There is a 
precedence in the literature for differences in peripheral cell populations in patients 
with depression including increased white blood cells (Rothermundt et al., 2001), and 
activated platelets (Musselman et al., 1996). Therefore, changes in cell types could 
contribute to differences in mRNA gene expression between depressed patients and 
controls and must be taken into account in future studies. If immune cells become 
activated following stress, such as moderate exercise, we could expect increases in 
mRNA in processed samples. Though we did not see changes in TF2B following 
moderate exercise in CFS and FMS subjects, similar studies with depressed patients are 
underway to determine changes in gene expression.  
 
Future directions 
 qPCR of peripheral blood cells permits simple, noninvasive, method to quantify 
gene expression in patients before and following treatment. However, in the study of a 
multi-faceted disease such as depression, three further lines of research are necessary. 
The first is to continue examining other depressed populations for candidate gene 
expression dysregulation. Specifically, it would be beneficial to further examine 
nondepressed controls currently on antidepressants or other psychotropic drugs, and 





medications.  In addition, testing depressed subjects on a moderate exercise task is of 
interest since the task is showing promise in differentiating patients with chronic fatigue 
and fibromyalgia syndromes from controls, disorders that have high rates of co-morbid 
depression. Current studies are underway in examining the effects of specific 
anticonvulsants on gene expression and symptoms in patients with CFS. The second line 
is biological research into the mechanisms of some of the candidate genes in animal 
models of depression. For example, employing animal models to examine the role of DBI 
in medication-resistance and anxiety symptomology; animal models of APP and NRG1 
dysregulation and potential neuronal dysfunction; continued research into the role of 
metabotropic receptors such as the purinergic, ASIC, and TRPV receptors, in animal 
models of depression. A better understanding of gene expression differences between 
groups as well as their biological function could help lead to novel drug targets and 
patient-specific medical care. Finally, gene expression candidates and animal studies 
could lead to the development of novel therapies, which in conjunction with gene 
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Inconsistent prior research suggests that isoflurane anesthesia may be an 
effective alternative to electroconvulsive therapy (ECT) in depression. The purpose of 
this study was to determine if isoflurane has antidepressant effects comparable to ECT, 
with less adverse effects on cognition. Patients with medication-refractory depression 
received an average of 10 treatments of bifrontal ECT (n=20) or isoflurane (n=8) over 3 
weeks. Mood and neurocognitive responses were assessed at pretreatment, 
posttreatment and 4-week follow-up. Both treatments produced reductions in 
depression scores at posttreatment (P<0.005) and follow-up (P<0.05); however, ECT had 
better antidepressant effect at follow-up in severity-matched patients (P<0.05, n=8). 
Immediately posttreatment, ECT (but not isoflurane) patients showed declines in 
memory, fluency, and processing speed (P<0.05); at follow-up, only autobiographical 
memory remained below pretreatment for ECT patients, but isoflurane patients had 
greater test-retest neurocognitive score improvement (P<0.05). Our data suggest that 
isoflurane has an antidepressant effect approaching ECT with less adverse 
neurocognitive effects.  
 
Introduction 
Although antidepressant medications are effective for many patients with 
depression, the rate of response to the first agent administered can be as low as 50%.  
For nonresponders to the first agent, the Sequenced Treatment Alternatives to Relieve 





as successive medication alternatives were tried (Rush et al., 2006) . Electroconvulsive 
therapy (ECT) is generally acknowledged to be the most effective treatment for severe 
and medication-refractory depression(UK ECT review group, 2003). Its remission rates 
are between 55-90%, even in patients whose depression fails to remit with multiple 
trials of medications (Prudic et al., 1996; Prudic et al., 2004; Khalid et al., 2008). 
Significant reduction in symptoms also occurs more rapidly with ECT than medications, 
typically in 2-4 weeks consisting of 8-14 treatment sessions. Though effective, ECT is 
associated with significant adverse cognitive effects such as retrograde amnesia, 
problems with concentration and attention, and other cognitive sequelae. With the 
notable exception of autobiographical memory problems, most adverse cognitive 
effects of ECT are reported to resolve within two weeks (Semkovska and McLoughlin, 
2010). Bifrontal ECT is equally effective to the more traditional bitemporal ECT and has 
less memory disruption (Dunne and McLoughlin, 2012). There is also a widespread 
public misunderstanding that the seizure induced by ECT may be painful and traumatic, 
and carries high risk of brain damage and personality change, making patients and 
family members reluctant to approve this treatment option (Payne and Prudic, 2009). 
For these reasons, this effective therapy has become a treatment of last resort 
(relegated to 5th, 6th or 7th step after the failure of other therapies per American 
Psychiatric Association guidelines) and ECT is administered to only about 100,000 
patients a year (Payne and Prudic, 2009). Thus, millions of patients suffering from major 
depression do not receive effective therapy, and others receive relief only after many 





It would be highly desirable to establish an alternative therapy that has similar 
benefits to ECT while minimizing any adverse neurocognitive effects and having wider 
social acceptability. One alternative meeting these criteria that has some prior data 
supporting its potential effectiveness in depression is deep inhalation anesthesia with 
isoflurane (ISO). Like ECT, deep anesthesia with ISO induces a brief state of 
electrocortical quiescence (burst suppression on electroencephalogram (EEG)), but does 
so without inducing convulsions or other seizure symptoms. Based on two preliminary 
studies directed by Langer, et al in Europe (Langer et al., 1985; Langer et al., 1995), a 
series of six treatments with ISO had similar efficacy to six ECT sessions in reducing 
depressive symptoms without causing memory loss. The first study was a pilot study 
showing reduction of depressive symptoms in 11 patients exposed to variable numbers 
of ISO treatments, and the second was a small double-blind study comparing 10 
depressed women treated with ISO vs. 10 treated with ECT for 6 sessions.  Assessments 
indicated cognitive improvement in the ISO group vs. declines in ECT group after 
treatment. Subsequent work by Engelhardt (Engelhardt et al., 1993) demonstrated 
similar antidepressant effect with a combined series of ISO treatments followed by ECT. 
A small open-label report by Carl, et al. (Carl et al., 1988) also suggested similar 
antidepressant efficacy of deep ISO anesthesia compared to ECT. In contrast, however, 
Greenberg, et al. (Greenberg et al., 1987) showed relatively little improvement with ISO 
treatments in a pilot study involving 6 elderly depressed patients (including 5 aged 74-
82 years). In another pilot study, Garcia-Toro, et al. (Garcia-Toro et al., 2001) treated 10 





24% reduction in depressive symptoms was noted on average, the clinical effect was not 
deemed sufficient after four treatments and patients were switched to ECT. In these 
negative studies, methodological concerns were that the number of treatments were 
fewer than are typically effective for ECT, treatment effects that initially seemed 
promising nevertheless were stopped, and in the latter study, a low concentration of 
sevoflurane was used instead of a high concentration of isoflurane. There was 
essentially a cessation of interest in this potential treatment until recently, when studies 
in animal models also indicated antidepressant effects of ISO anesthesia. In a pilot study 
in our lab, mice treated with a single dose of either high dose ISO or desipramine and 
assessed 24 hours later using the forced swim test showed reduced immobility times as 
compared to the control group, suggesting antidepressant efficacy (Tadler SC, 2009). To 
assess more enduring antidepressant effects, Wang et al (Wang L, 2012) administered 
isoflurane (2%) or halothane (1.5%) to adult male Sprague Dawley rats continuously for 
2 hours. Two weeks later, in a learned helplessness paradigm, isoflurane-treated rats 
had fewer failure trials and faster mean escape latency than naïve controls in the shuttle 
box avoidance task. Halothane-treated rats showed no antidepressant effects, 
suggesting that the reduced expression of learned helplessness is specific to isoflurane    
rather than a general effect associated with exposure to volatile anesthetics.  
Given the large number of patients with medication-refractory depression 
(including many who are under age 70, relatively healthy, and would be deemed good 
candidates for ISO anesthesia), and improvements in medical monitoring and 





anesthesia as an effective alternative therapy to ECT is warranted. As a small open-label 
comparability study, the present study’s primary objective was to examine whether 
deep ISO anesthesia shows similar efficacy to ECT in alleviating moderate to severe 
depression in medication-refractory patients.  The secondary objective was to evaluate 
whether a series of 10 treatments with deep ISO anesthesia over a 3 week period results 
better neurocognitive function at 24-48 hours after the last treatment and 4 weeks later 
than treatments with bifrontal ECT, a form of ECT previously shown to have lesser 
effects on memory on cognition than bitemporal ECT (Dunne and McLoughlin, 2012). 
 
Materials and Methods 
Participants 
This study was approved by the University of Utah Institutional Review Board 
(IRB Protocol No. 00025750) and all participants provided written informed consent. 
Participants included 28 patients aged 18-65 years with moderate to severe depression 
(Hamilton Rating Scale for Depression HRSD-24 score of 20 or higher). They were 
recruited from among patients referred for ECT to the University of Utah 
Neuropsychiatric Institute (UNI) based on unsatisfactory response and/or intolerance to 
(BPD).  Exclusions included: 1) primary psychotic disorder, dysthymia, or personality 
disorder; 2) significant premorbid cognitive impairment (defined as Mini-mental Exam 
score below 24); 3) unstable cardiovascular or cerebrovascular disease, 4) any other 
contraindication to ISO anesthesia; 5) pregnancy or 6) inability to consent.  Enrolled 





anticonvulsants which were discontinued (see Table A.1) while undergoing the study. In 
this open-label study, 20 patients were treated using the medical standard intervention, 
ECT, and 8 patients with the nonstandard intervention, ISO.  
Because initial tests revealed that the ECT patients had significantly greater 
depression severity than the ISO patients at Pretreatment, the responses of the ISO 
group were also compared to a severity-matched ECT subgroup (n=8); this ECT-Matched 
subgroup also had the same ratio of patients with BPD vs. MDD diagnoses as the ISO 
group (3 BPD/5MDD). All patients completed both Pretreatment and Posttreatment 




The design was an open-label, two-arm treatment trial, comparing 8-12 sessions 
of ECT vs. 10 sessions of ISO anesthesia treatments over a 2.5-3.5 week period.  Primary 
outcome measures included: 1) depressive symptoms assessed by clinical assessment 
using the HRSD-24 by blinded investigators, and patient self-ratings on the 16-item  
Quick Inventory of Depressive Symptomatology Self Report (QIDS-SR16) 
2) neurocognitive function assessed by tests of memory, executive function, and 
processing speed. HRSD-24 and cognitive assessments were completed 3 times:  1) 
Pretreatment, 2) 24-48 hours after the last treatment session (Posttreatment), and 3) 4 
weeks after the last treatment session (Follow-up).  In 12 ECT and all 8 ISO patients, 





     ECT-All  ECT-Matched  ISO 
Gender (Male/Total)    12/20   6/8   3/8 
Diagnosis (MDD/BPD)    16/4   5/3   5/3 
Mean Age (SEM)    41.60 (2.80)a  41.38 (5.39)  35.38 (3.50) 
Severity (Pretreatment HRSD-24)  36.55*   28.00   26.63 
Mean WTAR (SEM)   107.90 (2.19)a    107.88 (4.67)    117.00 (5.01) 
Pretreatment Medications (# of patients): 
    SSRI       9                   5      2  
 SNRI       8   1      3 
 NRI       3   1    0 
Lithium/valproate     5                 1    2 
 Antipsychotic      8                 2    5 
 Anticonvulsantb    14                   6    2 
 No psychotropic meds      3                 1     1 
* ECT-All > ISO, p<0.05, a Group differences nonsignificant, p>0.12 
b Anticonvulsant medications were stopped during treatment sessions in all groups.  
Table A.1 Group Demographics, Depression Severity, Intellectual Level and Medications 
 
 session, to provide a more continuous picture of the rate of symptom change. 
 
Treatment procedures 
Patients received standard monitoring as recommended by the American Society 
of Anesthesiologists (ASA).  
Procedures for the ECT treatment group. Induction was performed by an 





a hand followed by neuromuscular blockade using succinylcholine (adjusted by height, 
1-2 mg/inch).  Then, 60-120 seconds later, the bifrontal ECT stimulus was administered 
(SpECTrum 5000Q Electroconvulsive Therapy Unit, Mecta Corportation, Tualatin, OR). 
Visual evidence of tonic-clonic seizure was confirmed by observation in the hand that 
remained isolated from the systemic circulation. ECT procedure time averaged 20 
minutes, with 30-45 minutes required for postprocedure recovery. ECT treatments were 
repeated approximately every other day for a total of 8-12 treatments (mean 9.6, 
standard error (SEM) 0.34), based on clinically determined need.  
Procedures for the ISO treatment group. As with ECT, anesthetic induction was 
achieved with methohexital (1-3 mg/kg IV) and neuromuscular blockade was 
accomplished with succinylcholine (adjusted by height, 1-2 mg/inch). Patients were 
infused with 500 ml of lactated Ringers solution to help reduce risk of hypotension. The 
patient’s airway was secured via endotrachial intubation. The EEG-derived bispectral 
index (BIS) was monitored continuously using an Aspect A1000 monitor (BIS v. 3.3, 
Aspect Medical Systems, Newton MA), along with end-tidal concentration of isoflurane, 
carbon dioxide and oxygen. Isoflurane concentration was initially at 4% with high flow 
oxygen until >80% EEG burst suppression; it was then decreased to two times the age-
adjusted Minimum Alveolar Concentration (MAC) for the patient and oxygen flows 
reduced. This level of burst suppression was maintained for 15 minutes (as per Langer, 
et al. (Langer et al., 1985; Langer et al., 1995)) and then isoflurane was discontinued and 
the patient allowed to awaken. ISO procedure time averaged 40-45 minutes. Emergence 





that rapidly removes residual inhaled anesthestics, reducing post procedure recovery 
time to 15-20 minutes. Significant hemodynamic alteration (change in heart rate or 
blood pressure more than 20% from baseline) was treated in standard fashion with 
appropriate agents (phenylephrine, intravenous fluids, etc.) as per the anesthesiologist’s 
(KS’s) discretion. ISO treatments were repeated approximately every other day for a 
total of 10 treatments. 
 
Neurocognitive testing 
At Pretreatment, all patients completed the Mini-mental Exam and the Wechsler 
Test of Adult Reading (WTAR) to confirm that intellectual levels were within normal 
limits and generally comparable across groups. Mini-mental scores were all > 26 and did 
not differ for the ECT-All, ECT-Matched and ISO groups (means = 28.89, 28.94 and 29.22, 
respectively, P>0.38). WTAR scores and age also did not differ significantly (P>0.12; 
Table A.1), but there was a weak trend toward higher WTAR and lower age in the ISO 
group. To ensure that our findings were not influenced by these subtle differences, both 
WTAR and age were retained as covariates in our group comparisons.  
At Pretreatment, Posttreatment and Follow-up, the following battery of tests 
were completed. To assess retrograde amnesia, subjects completed the 
Autobiographical Memory Interview-Short Form (AMI) (Fraser et al., 2008; Semkovska et 
al., 2012). To assess anterograde amnesia, they completed the Hopkins Verbal Learning 
test, including Immediate Recall, Delayed Recall,  and Discrimination measures (Norman 





3rd edition (Theisen et al., 1998; Wroolie et al., 2006). To assess speed of information 
processing, they completed the Symbol Search and the Digit-Symbol Coding subtests 
that make up the Processing Speed Index (PSI) of the Wechsler Adult Intelligence Scale 
(Longman et al., 2007; Wisdom et al., 2012). To screen executive function, they also 
completed the Delis Kaplan Verbal Fluency Test where they were asked to generate as 
many words as possible in 60 seconds beginning with a specific letter (Tombaugh et al., 
1999; Delis, 2001). 
 
Statistical analysis 
Two sets of analyses were performed. First, ECT-All patients (n=20) were 
compared with the ISO patients (n=8) for HRSD-24 scores and for each of the 
neurocognitive performance scores at Pretreatment, Posttreatment and Follow-up using 
a mixed model repeated measures ANCOVA with Group (2) as a between-subjects factor 
and Time (3) as a within-subjects factor.  For the neurocognitive measures, both age and 
intellectual level as indexed by WTAR score were included as covariates. For the QIDS-SR 
scores, which were obtained before and throughout the ECT and ISO treatment series, a 
Group (2) x Time (4) analysis was used, where sampling times were before the first, 
fourth, seventh and tenth/last treatment. When ANCOVAs indicated significant effects, 
between-group and within-group comparisons among means were performed; for the 
neurocognitive measures, these means were adjusted for age and WTAR. For measures 
were ANCOVAs yielded significant effects, second set of mean comparisons were 





changes in performance after treatment between groups, Posttreatment and Follow-up 
means were compared between-groups after adjustment for the Pretreatment score on 
that test as well as WTAR. Alpha level was conservatively set at P< 0.05 two-tailed, even 
where our predicted outcomes were directional (e.g., ISO > ECT for neurocognitive 
measures following treatment), in an effort to limit the increase in false positive findings 
associated with multiple dependent variables. Cohen’s d estimates of effect sizes were 
also generated (using pooled standard deviations) for each significant group difference. 
 
Results 
Antidepressant effects of ECT and ISO 
For the HRSD-24 scores based on clinical interviews, a main effect of Times (F = 
51.9, d.f. = 2,52, p < 0.0001) and a significant Group X Time interaction was obtained (F 
= 4.58, d.f.=1,52, p < 0.05). Subsequent comparisons showed that although the ECT-All 
group initially had higher depression severity than the ISO group based on Pretreatment 
HRSD-24 scores (p < .008), the scores of both groups decreased from Pretreatment 
levels at Posttreatment (p < 0.0001 for ECT, p < 0.005 for ISO), and these significant 
decreases persisted at 4-week Follow-up (p < 0.0001 for ECT, p < 0.033 for ISO). When 
ECT-All was compared with the ISO group, they did not differ in HRSD-24 at 
Posttreatment or Follow-up, with both groups reducing symptom severity to the mild 
range (see Figure A.1). The ECT-Matched and ISO patients (n=8 per group) had 
comparable HRSD-24 scores at Pretreatment and Posttreatment (p = 0.78), but the ECT-







































Figure A.1. Scores on Hamilton Rating Scale for Depression (HRSD-24) prior to 
treatment (Pretreatment), 24-48 hours after the last treatment (Post), and at a 
4 week return visit (Follow-up).  Treatment with ECT and ISO results in 
significant decrease in HRSD-24 depressive symptoms at both Post and Follow-
up, compared to Pretreatment. The ECT-Matched and ISO groups had 
comparable decreases at Post-treatment, but ECT-Matched maintained these 
low scores better at Follow-up.  
+ ECT-All vs. ISO p < .05, & ECT-Matched vs. ISO p < .05, *Within group ECT-All 
Change from Pretreatment p < .05, # Within group ECT-Matched Change from 


























follow-up (8.9 vs. 17.6, p < 0.036, d = 1.39; Figure A.1). Self-reported depressive 
symptoms (QIDS-SR16) obtained prior to the ECT or ISO treatment sessions did not 
differ between the groups at any time point (Group x Time F = 0.84, d.f.=3,70, p = 0.55), 
and there was similar steady improvement in all three groups across the treatment 













































Figure A.2. Scores on the Quick Inventory of Depression Scale (QIDS-SR16) self-
report form over 21 days of treatment (treatment sessions 1-10). For brevity, results 
are depicted showing change over each week, from Day 1 (prior to 1st treatment), 
Day 7 (prior to 4th treatment), Day 14 (prior to 7th treatment), Day 21 (prior to 10th 
treatment).  
+ ECT-All vs. ISO p < .05, & ECT-Matched vs. ISO p < .05, *Within-group ECT-All 
Change from Day 1 p < .05, # Within-group ECT-Matched Change from Day 1 p < .05, 





Neurocognitive measures: Overall analyses 
After adjustment for differences in age and WTAR, a significant Group x Time 
interaction was obtained for six of the eight neurocognitive measures: Hopkins 
Immediate Recall and Discrimination, Logical Memory I and II, Fluency and AMI (F’s = 
6.49, 5.23, 5.56, 7.99, 10.03 and 6.83, d.f. = 2,44, p < 0.01 – p < 0.001). For the PSI, this 
interaction approached significance (p = 0.067), but the main effect of Group was more 
robust (F = 8.12, d.f. = 1, 22, p < 0.01). For Hopkins Delayed Recall, no reliable effects 
were seen (p > 0.15). Subsequent analyses focused on comparisons of adjusted means 
in the seven neurocognitive measures where overall analyses were significant (see 
Tables A.2 and A.3). 
 
Retrograde amnesia 
For age- and WTAR-adjusted AMI scores, no group differences were obtained at 
Pretreatment, but the ISO group had significantly better recall for dates and details of  
real-life autobiographical events at Posttreatment and Follow-up than both the ECT-All 
and the ECT-Matched groups (Table A.2).  Within-group comparisons indicated 
significant performance decrements between Pre- and Posttreatment in all groups (p < 
0.05 for ISO, p < 0.001 for ECT-All and ECT-Matched). These decrements persisted at 
Follow-up. When responses after treatment were further adjusted for Pretreatment 
performance, the ECT-All group showed greater decline in AMI performance at both 
Posttreatment and Follow-up and the ECT-Matched showed greater decline at Follow 





Table A.2. Neurocognitive Means (SEM) at Pretreatment, Posttreatment and Follow-





















Pretreatment   Post-Treatment  Follow-up 
   Adj. Mean (SEM)  p Adj. Mean (SEM)  p Adj. Mean (SEM)  p 
Hopkins Immed Recall 
  ECT-All     45.04 (2.49)     0.41    42.02 (3.10)    0.01 50.83 (2.57)    0.10 
  ECT-Matched    47.63 (3.33)     0.39  51.45 (4.77)     0.18 58.23 (3.90)     0.64 
  ISO      49.40 (4.20)  61.08 (5.23)  60.34 (4.58) 
Hopkins Delay Recall  
  ECT-All  44.03 (2.69)    0.18 40.65 (3.22)    0.17 50.05 (2.30)    0 .31 
  ECT-Matched  48.25 (3.55)    0.28 52.68 (3.61)     0.41 55.17 (2.47)     0.94 
  ISO   51.80 (4.54)  56.76 (5.42)  55.25 (4.10) 
Hopkins Discrimination  
  ECT-All  47.55 (2.38)    0.24 35.56 (2.94)    0.001 46.66 (1.59)    0.01 
  ECT-Matched  50.77 (3.26)    0.48 41.42 (4.87)    0.11 49.33 (2.43)    0.09 
  ISO   53.44 (4.01)  56.05 (4.95)  55.93 (2.83) 
Logical Memory I 
  ECT-All   9.42 (0.55)    0.23  8.69 (0.73)    0.004 11.45 (0.69)    0.03 
  ECT-Matched   9.00 (0.79)    0.07 10.31 (0.90)    0.03  12.91 (1.01)    0.13 
  ISO   10.83 (0.94)  13.49 (1.19)  15.32 
 




























Pretreatment   Post-Treatment  Follow-up 
   Adj. Mean (SEM)  p Adj. Mean (SEM)  p Adj. Mean (SEM)  p 
Logical Memory II 
  ECT-All  10.53 (0.54)    0.85  8.18 (0.83)    0.001 11.59 (0.58)    0.009 
  ECT-Matched  10.54 (0.81)    0.67 10.70 (1.18)    0.02 13.08 (0.61)    0.03 
  ISO   10.31 (0.91)  15.40 (1.35)  15.54 (1.18) 
Delis Kaplan Fluency 
  ECT-All  10.32 (0.63)    0.11     6.00 (0.79)    0.01  9.47 (0.78)     0.75 
  ECT-Matched    9.94 (0.98)    0.33   6.90 (1.12)    0.05 10.00 (0.68)    0.89 
  ISO     8.20 (1.06)   11.14 (1.34)  10.02 (1.39) 
Autobiographical Mem 
  ECT-All  53.39 (1.10)    0 .62 37.18 (1.88)    0.002 37.14 (1.93)    0.01 
  ECT-Matched  52.71 (1.94)    0.55 40.28 (2.56)    0.04 39.36 (2.41)    0.04 
  ISO   54.53 (1.85)  50.54 (3.17)  48.79 (3.45) 
Processing Speed Index  
  ECT-All  93.22 (3.90)    0.03 87.40 (3.36)    0.004 97.89 (3.56)    0.01 
  ECT-Matched  91.16 (8.04)    0.09 91.44 (6.73)    0.09 99.71 (6.99)    0.08 
  ISO            112.20 (6.58)  109.75 (5.67)  119.96 (2.26) 
 






Table A.3. Neurocognitive Means (SEM) at Posttreatment and Follow-up, Adjusted for 





















 Post-Treatment    Follow-up  
    Adj. Mean (SEM)  p  Adj. Mean (SEM)  p  
Hopkins Immediate Recall 
  ECT-All   43.48 (2.26)    0.01  51.48 (1.88)    0.05 
  ECT-Matched   54.49 (3.09)    0.40  60.07 (2.71)     0.84 
  ISO    57.41 (3.76)   59.41 (3.15) 
Hopkins Delay Recall  
  ECT-All   42.70 (2.43)    0.09  51.22 (1.75)    0.65 
  ECT-Matched   55.49 (2.21)    0.78  56.96 (0.99)    0.28 
  ISO    51.61 (4.10)   52.87 (2.92) 
Hopkins Discrimination  
  ECT-All   36.28 (2.97)    0.01  46.24 (1.63)    0.01 
  ECT-Matched   43.03 (4.49)    0.19  50.52 (1.68)    0.046 
  ISO    55.09 (5.18)   55.93 (2.83) 
Logical Memory I 
  ECT-All    8.94 (0.67)    0.005  11.51 (0.68)     0.04 
  ECT-Matched   11.22 (0.92)     0.21  13.98 (0.77)    0.80 
  ISO    13.05 (1.07)   15.08 (1.37) 
 




























 Post-Treatment    Follow-up  
    Adj. Mean (SEM)  P  Adj. Mean (SEM)  P 
Logical Memory II 
  ECT-All      8.25 (0.72)    0.001  11.54 (0.54)    0.002 
  ECT-Matched   11.12 (0.88)    0.006  13.29 (0.44)    0.006 
  ISO    15.48 (1.12)   15.65 (1.00) 
Delis Kaplan Fluency 
  ECT-All    5.87 (0.71)    0.001   9.18 (0.67)     0.30 
  ECT-Matched    6.58 (0.69)     0.001   9.69 (0.43)    0.37 
  ISO    11.44 (1.17)   10.64 (1.22) 
Autobiographical Memory 
  ECT-All   37.70 (1.81)    0.003  37.31 (1.60)    0.002 
  ECT-Matched   41.36 (2.38)    0.07  39.60 (2.06)    0.02 
  ISO    49.24 (2.95)   48.14 (2.64) 
Processing Speed Index  
  ECT-All   89.68 (2.76)    0.02  101.02 (2.41)    0.02 
  ECT-Matched   95.72 (5.45)    0.23  107.85 (3.99)    0.13 
  ISO    104.05 (4.69)   113.36 (3.93) 
 
p-values are for adjusted mean comparisons versus ISO.  
 







For the Verbal Fluency measure, no group differences were significant at 
Pretreatment or Follow-up, but the ISO group had significantly better performance 
immediately Posttreatment (Table A.2). These Posttreatment group differences were 
maintained after adjustment for Pretreatment scores (Table A.3). Within-group 
comparisons indicated that the ECT-All and ECT-Matched groups showed decrements in 
Fluency at Posttreatment (p < 0.001) while the ISO group showed a slightly enhanced 
performance (p < 0.05). Both ECT groups showed significant increases in Fluency 
between Posttreatment and Follow-up (p < 0.01) while the ISO group’s Fluency score did 
not differ reliably between those times (p = 0.19).  
 
Anterograde amnesia 
Among the Hopkins Verbal Learning measures, which involve memory for spoken 
word lists, there were no group differences at Pretreatment after adjustment for age 
and WTAR. At Posttreatment, the ISO group had significantly better performance than 
the ECT-All group for both Immediate Recall and Discrimination scores, but did not differ 
significantly from the ECT-Matched group (Table A.2). After further adjustment for 
Pretreatment performance, the ISO group’s Immediate Recall and Discrimination scores 
were superior to the ECT-All group at Follow-up as well as Posttreatment, and their 
Discrimination scores at Follow-up were better than the ECT-Matched group (Table A.3). 
Within-group comparisons showed that both the ISO and ECT-matched groups had 





0.05 respectively) while the ECT-All group did not change. For Discrimination, the ECT-All 
and ECT-Matched groups both declined from Pretreatment to Posttreatment (p < 0.01 
and p < 0.05 respectively) while the ISO group showed no real change. As noted 
previously, Hopkins Delayed Recall showed no significant effects.  
 For the Logical Memory tests I and II, which involve immediate and delayed 
recall of spoken passages, no significant group differences were obtained at 
Pretreatment after adjustment for age and WTAR. At Posttreatment, the ISO group had 
better performance on both tasks than either of the ECT groups (Table A.2). At Follow-
up, they continued to have better delayed recall (test II) than either of the ECT groups 
and their immediate recall for passages (test I) was still reliably better than the ECT-All 
group. After adjustment for Pretreatment performance, they had better test I 
performance than the ECT-All group but no longer differed from the ECT-Matched group 
at either Posttreatment or Follow-up; however, the ISO group still showed better test II 
performance than either ECT-Matched or ECT-All groups at both times (Table A.3). 
Within-group comparisons indicated that the ISO group had significant increases and 
the ECT-All group had significant decreases in test II scores at Posttreatment vs. 
Pretreatment (p < 0.05). Both ISO and ECT-Matched had increases in test I scores at 
Posttreatment (p < 0.05).  All groups showed better Logical Memory I and II scores at 








Speed of processing 
For the Processing Speed Index scores, the ISO group had significantly better 
performance than ECT-All at Pretreatment, Posttreatment and Follow-up even with 
adjustment for WTAR and age (p < 0.03; Table A.2). Even though their responses were 
only marginally different from ISO (p < 0.09), the ECT-Matched group performed slightly 
worse on average than the ECT-All group, suggesting that the lack of reliable difference 
was due to the smaller sample size rather than depression severity. Only the ECT-All 
group showed a significant drop in PSI score at Posttreatment (p < 0.05), and this led to 
a significant group difference between the ISO and ECT-All group at Posttreatment after 
further adjustment for Pretreatment scores (Table A.3). All groups showed higher PSI 




The results of this open label study supported our primary hypothesis that a 
series of 10 sessions of deep anesthesia with ISO is effective as an antidepressant 
intervention for patients with medication-refractory depression. The improvement in 
HRSD-24 scores and QIDS-SR16 scores immediately after completion of treatment was 
similar in the nonstandard ISO treatment to the standard ECT treatment. Although there 
was somewhat better maintenance of the decrease in HRSD-24 depressive symptom 
scores among the 8 severity-matched ECT patients one month later, the ISO group still 





The antidepressant effect of ISO indicated by these observations is very similar 
to the original reports by Langer et al. (Langer et al., 1985; Langer et al., 1995).  The 
explanation for why our results were more positive than other later studies may be due 
to closer adherence to the original protocols, particularly in patient age, duration of 
each ISO session, and use of more ISO treatment sessions. As suggested by the QIDS-
SR16 self-report data in Figure A.2, much of the beneficial effect of ISO occurred in 
sessions 5-10, while Garcia-Toro et al terminated their treatments after only four 
sessions, and they used sevoflurane which might be less effective than ISO, especially if 
sustained EEG burst suppression is needed for a clinical benefit (Garcia-Toro et al., 
2001). We also restricted our sample to persons aged 65 and younger, in part because 
of the increased likelihood of adverse blood pressure and other cardiovascular concerns 
in elderly patients, like those studied by Greenberg et al. (Greenberg et al., 1987). We 
also were able to reduce side effects (nausea, vomiting, and disorientation) and shorten 
the time to full recovery after each session by use of the ANEclear™. 
 
Cognitive effects 
The neurocognitive assessments made as part of this study indicate that even 
with 10 sessions of ISO anesthesia over a three week period, there was no significant 
performance decrement on any of the traditional neurocognitive measures. In fact, the 
ISO patients showed significant improvements in word fluency, nonverbal processing 
speed, logical memory and immediate and delayed recall of newly learned verbal 





combined effects of decreased depressive symptoms (which has been linked to 
response slowing and other performance deficits) and practice (Wroolie et al., 2006; 
Attix et al., 2009; Semkovska and McLoughlin, 2010). The one measure where there was 
any suggestion of a performance decline with ISO treatment was the Autobiographical 
Memory Interview. This scale has intrinsic flaws because the responses given at the 
initial interview are designated as correct without verification. Consequently, when 
retesting occurs, the individual’s performance can worsen but cannot show 
improvement, and any answers that differ from the original ones (even if the patient has 
remembered more accurately when retested) are scored as errors. Recently, Semkovska 
et al. found that when retested after 2 months, healthy controls as well as depressed 
patients never treated with ECT showed similar mild declines in AMI performance, 
which they labeled as consistency errors rather than true memory deficits (Semkovska 
et al., 2012). For the ISO patients, their small Posttreatment decrements in AMI scores 
were similar in magnitude to expected test-retest consistency errors, and their 
performance was superior to the ECT patients both immediately after the last treatment 
and one month later. Thus, multiple sessions of ECT led to persistent AMI deficits that 
were not seen after multiple sessions of ISO.  
The effectiveness of bifrontal ECT on depressive symptoms was never in doubt 
(Prudic et al., 1996; 2003; Prudic et al., 2004; Khalid et al., 2008), but our results on the 
time course and relative magnitude of other neurocognitive decrements are important 
to note. When tested within 24-48 hours after their last ECT session, the ECT-All group 





ability to discriminate between words previously heard versus other words, and 
processing speed. The ECT-Matched group had fewer performance deficits, but still 
showed significant reductions in word fluency and discrimination at Posttreatment, and 
they failed to match the practice-related improvement seen in the ISO group for delayed 
recall of passages.  After one month, however, performance of the ECT patients on all 
tests except for the AMI returned to or exceeded Pretreatment levels. This is consistent 
with the meta-analysis by Semskovska and McLoughlin (Semkovska and McLoughlin, 
2010) , which noted that neurocognitive deficits linked to bifrontal ECT were mainly 
limited to the first 3 days Posttreatment, and at 15 days Posttreatment, there was 
evidence of improvement in both memory and executive function (Semkovska and 
McLoughlin, 2010). Comparisons between means adjusted for pretreatment task 
performance and intellectual level indicated, however, that the improvements 4 weeks 
after treatment in the ISO group were greater than the full ECT sample for several 
cognitive measures, including immediate recall of newly learned words and passages, 
word discrimination, delayed recall of passages, and processing speed. Possibly the ISO 
patients were able to benefit more from practice at the testing done 24-48 hours after 
the last treatment when many ECT patients were experiencing significant cognitive 
impairment. Also, the ECT-Matched group had improvements as great as the ISO group 
for all measures except word discrimination, delayed recall of passages and 
autobiographical memory. This suggests that initial depression severity contributes to 
lesser posttreatment improvement in immediate recall of words and passages and 









There are several study limitations to acknowledge. The study was open-label 
rather than randomized, and the group sizes were modest. Replication in a larger 
randomized trial is needed to confirm these findings. More of the severely depressed 
patients chose ECT than ISO, which was managed by creating a smaller ECT-Matched 
subgroup to examine along with the full ECT and ISO groups. The effectiveness of ISO for 
the most severely depressed patients is still uncertain. Also, some of the ECT patients 
had 8 or 12 rather than 10 treatments, titrated to clinical effectiveness, but our IRB 
approval restricted the ISO treatment series to 10. This factor may have contributed to 
the slightly better antidepressant outcome for the ECT-Matched patients at 4-week 
follow-up. Finally, all of the patients in the study had medication-refractory moderate to 
severe depression, so that future research is needed to examine whether ISO anesthesia 
may be an effective treatment in milder and medication-responsive depression. This 
small open-label study indicates the ISO may be another option for patients with 
moderate to severe depression (both with MDD and BPD diagnoses) who find 
medications ineffective or are unable to tolerate their side effects. Like transcranial 
magnetic and direct current stimulation, magnetic seizure therapy and other novel 
treatment options, it is important to have explore the comparable efficacy as well as 





al., 2008; Allan et al., 2011; Loo et al., 2012). It would also add value if future studies 
examine whether these alternative therapies, including ISO anesthesia, convey their 
antidepressant effects through the same or different pathways as ECT, such as by 
decreasing frontal cortical connectivity (Perrin et al., 2012) or altering the expression of 
the same neuronal and immune genes (Iacob et al., 2013). 
 
Implications 
This small study shows that a series of 10 treatment sessions with deep 
inhalation isoflurane anesthesia has an antidepressant effect in moderate to severe 
medication-refractory depression approaching that of bifrontal ECT.  Neurocognitive 
performance of ISO-treated patients was superior to ECT-treated patients immediately 
after the last treatment (when only ECT was associated with worsened performance 
relative to Pretreatment). ISO patients continued to perform better 4 weeks later, 
although performance in ECT patients showed considerable improvement between 
those tests. Given the small size and lack of randomization in this study, a much larger 
randomized and blinded study is required, preferably one designed to examine whether 
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